EXHBIIT 99.1
AGREEMENT AND PLAN OF MERGER
Dated as of June 10, 2001
Among
INSTITUTO GRIFOLS, S.A.,
SI MERGER CORP.
AND
SERACARE, INC.
TABLE OF CONTENTS
Page
ARTICLE I THE SPIN-OFF AND THE MERGER........................................2
Section 1.1 The Spin-Off...................................................2
Section 1.2 The Merger.....................................................2
Section 1.3 Effective Time of the Merger...................................2
Section 1.4 Company Actions................................................2
ARTICLE II THE SURVIVING CORPORATION.........................................3
Section 2.1 Certificate of Incorporation...................................3
Section 2.2 By-laws........................................................3
Section 2.3 Board of Directors and Officers................................3
Section 2.4 Effects of Merger..............................................3
ARTICLE III CONVERSION OF SHARES.............................................3
Section 3.1 Conversion or Cancellation of Shares...........................3
Section 3.2 Surrender and Payment..........................................4
Section 3.3 Dissenting Shares..............................................6
Section 3.4 Stock Options..................................................6
Section 3.5 Warrants.......................................................7
Section 3.6 Stockholders Meeting...........................................7
Section 3.7 Closing........................................................7
Section 3.8 Transfer Taxes.................................................8
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PURCHASER.......................8
Section 4.1 Organization, Standing and Power...............................8
Section 4.2 Authority; Non-Contravention...................................8
Section 4.3 Financing......................................................9
Section 4.4 Brokers........................................................9
Section 4.5 Share Ownership................................................9
ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE COMPANY.....................10
Section 5.1 Organization, Standing and Power..............................10
Section 5.2 Capital Structure.............................................10
Section 5.3 Subsidiaries..................................................11
Section 5.4 Authority; Non-Contravention..................................11
Section 5.5 SEC Documents; Financial Statements...........................12
Section 5.6 Books and Records.............................................13
Section 5.7 Absence of Undisclosed Liabilities............................14
Section 5.8 Accounts Receivable...........................................14
Section 5.9 Inventory.....................................................14
Section 5.10 Absence of Certain Changes or Events........................14
Section 5.11 Litigation..................................................17
i
Section 5.12 Compliance with Law.........................................17
Section 5.13 Employee Plans..............................................20
Section 5.14 Employment Relations and Agreements.........................22
Section 5.15 Contracts...................................................23
Section 5.16 Environmental Laws and Regulations..........................25
Section 5.17 Real Property and Leases....................................27
Section 5.18 Customers...................................................29
Section 5.19 Suppliers...................................................29
Section 5.20 Intellectual Property.......................................29
Section 5.21 Insurance...................................................30
Section 5.22 Takeover Statutes...........................................30
Section 5.23 Taxes.......................................................30
Section 5.24 Accounts; Lockboxes; Safe Deposit Boxes.....................31
Section 5.25 Brokers. (a)...............................................31
Section 5.26 Certain Interests...........................................31
Section 5.27 Fairness Opinion............................................31
Section 5.28 Volume of Plasma Collected..................................31
Section 5.29 Disclosures.................................................32
Section 5.30 Life Sciences...............................................32
ARTICLE VI REPRESENTATIONS AND WARRANTIES REGARDING SUB.....................32
Section 6.1 Organization and Standing.....................................32
Section 6.2 Authority; Non-Contravention..................................32
ARTICLE VII COVENANTS RELATING TO CONDUCT OF BUSINESS.......................33
Section 7.1 Conduct of Business by the Company Pending the Merger.........33
Section 7.2 Consultation with Purchaser...................................36
Section 7.3 Conduct of Business of Sub Pending the Merger.................36
ARTICLE VIII ADDITIONAL AGREEMENTS..........................................36
Section 8.1 Proxy Statement...............................................36
Section 8.2 Indemnification...............................................37
Section 8.3 Additional Agreements.........................................39
Section 8.4 Stockholders' Approval and Board of Directors
Recommendation................................................40
Section 8.5 No Solicitation...............................................41
Section 8.6 Directors.....................................................42
Section 8.7 Access to Information, Employees and Company Properties.......42
Section 8.8 Spin-Off......................................................43
Section 8.9 Governmental Filings..........................................43
Section 8.10 Timely Payment..............................................43
Section 8.11 Standstill Agreement........................................43
Section 8.12 Public Announcements........................................44
Section 8.13 Financing...................................................44
ii
ARTICLE IX CONDITIONS PRECEDENT.............................................45
Section 9.1 Conditions to Each Party's Obligation to Effect the Merger....45
Section 9.2 Additional Conditions to Obligation of the Company to
Effect the Merger.............................................45
Section 9.3 Additional Conditions to Obligation of Purchaser and Sub
to Effect the Merger..........................................47
ARTICLE X TERMINATION, AMENDMENT AND WAIVER.................................50
Section 10.1 Termination by Mutual Consent...............................50
Section 10.2 Termination by Either Purchaser or the Company..............50
Section 10.3 Termination by Purchaser....................................51
Section 10.4 Termination by the Company..................................51
Section 10.5 Effect of Termination and Abandonment.......................51
ARTICLE XI MISCELLANEOUS....................................................53
Section 11.1 Non-Survival of Representations, Warranties and
Agreements....................................................53
Section 11.2 Notices.....................................................53
Section 11.3 Fees and Expenses...........................................55
Section 11.4 Publicity...................................................55
Section 11.5 Specific Performance........................................55
Section 11.6 Assignment; Binding Effect..................................55
Section 11.7 Entire Agreement............................................55
Section 11.8 Amendment...................................................56
Section 11.9 Governing Law...............................................56
Section 11.10 Consent to Jurisdiction.....................................56
Section 11.11 Counterparts................................................56
Section 11.12 Headings and Table of Contents..............................56
Section 11.13 Interpretation..............................................56
Section 11.14 Waivers.....................................................57
Section 11.15 Incorporation of Document...................................57
Section 11.16 Severability................................................57
Section 11.17 Subsidiaries; Knowledge of the Company......................57
Company Disclosure Letter
SCHEDULES
2.3 - Directors
9.3 - List of Consents
EXHIBITS
A. Form of Certificate
iii
Defined Terms Index
SECTION
Accounts Receivable..................................................5.8, 5.10
Agreement.............................................................Preamble
Alternative Proposal.......................................................8.5
Blue Sky Laws..............................................................4.2
Books and Records..........................................................5.6
CERCLA....................................................................5.16
Certificate of Merger......................................................1.3
Certificates...............................................................3.2
Change in Company Recommendation...........................................8.4
CIBC World Markets........................................................5.25
Claim......................................................................8.2
Closing....................................................................3.7
Closing Date...............................................................3.7
Code......................................................................5.13
Commitment Letter..........................................................4.3
Common Stock..........................................................Recitals
Company...............................................................Preamble
Company Benefit Plan......................................................5.13
Company Disclosure Letter..................................................5.2
Company Expenses..........................................................10.5
Company Financial Statements...............................................5.5
Company Products and Services.............................................5.12
Company Property(ies).....................................................5.17
Company Recommendation.....................................................8.4
Company Reports............................................................5.5
Company SEC Documents......................................................5.5
Company Termination Fee...................................................10.5
Company Termination Fee Event.............................................10.5
Confidentiality Agreement..................................................8.7
Contracts.................................................................5.15
Customers.................................................................5.18
DGCL..................................................................Recitals
Dissenting Shares..........................................................3.3
Distribution..........................................................Recitals
Distribution Ancillary Agreements..........................................1.1
Effective Time.............................................................1.3
employee benefit plan.....................................................5.13
Environment...............................................................5.16
Environmental Laws........................................................5.16
Environmental Liabilities.................................................5.16
Environmental Permits.....................................................5.16
ERISA.....................................................................5.13
iv
excess parachute payment..................................................5.13
Exchange Act...............................................................3.4
Exchange Agent.............................................................3.2
Exchange Instructions......................................................3.2
Former Company Properties.................................................5.16
FTC........................................................................8.3
Governmental Entity........................................................4.2
Hazardous Substances......................................................5.16
HSR Act....................................................................4.2
Indemnified Parties........................................................8.2
Industry Compliance Entities..............................................5.12
Intellectual Property Rights..............................................5.20
knowledge................................................................11.17
Leased Property...........................................................5.17
Liens.....................................................................5.17
Life Sciences.........................................................Recitals
Matching Offer.............................................................8.5
Material Adverse Change....................................................4.2
Material Adverse Effect....................................................4.2
Merger................................................................Recitals
Merger Consideration.......................................................3.1
Notice of Superior Proposal................................................8.4
Option(s)..................................................................3.4
OSHA......................................................................5.12
Owned Property............................................................5.17
Payment Fund...............................................................3.2
Permits...................................................................5.12
Permitted Liens...........................................................5.17
Person.....................................................................3.2
Personnel.................................................................5.10
Preferred Stock............................................................5.2
Prohibited transaction....................................................5.13
Proxy Statement............................................................8.1
Purchaser.............................................................Preamble
Purchaser Expenses........................................................10.5
Purchaser Termination Fee.................................................10.5
Purchaser Termination Fee Event...........................................10.5
Reference Balance Sheet....................................................5.5
Representatives............................................................8.7
SEC........................................................................5.5
Securities Act.............................................................5.4
Separation Agreement..................................................Recitals
Share(s)...................................................................3.1
Special Meeting............................................................3.6
Spin-Off..............................................................Recitals
Spin-Off Agreements........................................................1.1
v
Stock Plan.................................................................5.2
Sub...................................................................Preamble
Subsidiary...............................................................11.17
Superior Proposal..........................................................8.5
Surviving Corporation......................................................1.2
Tax.......................................................................5.23
Tax Return................................................................5.23
Third Party................................................................8.5
Voting Agreements.....................................................Recitals
VSI Advisors..............................................................5.25
Warrant(s).................................................................3.5
Window Period..............................................................8.4
vi
AGREEMENT AND PLAN OF MERGER
THIS AGREEMENT AND PLAN OF MERGER (this "AGREEMENT"), dated as of
June 10, 2001, by and among Instituto Grifols, S.A., a company organized under
the laws of Spain ("PURCHASER"), SI Merger Corp., a Delaware corporation and a
wholly owned subsidiary of Purchaser ("SUB"), and SeraCare, Inc., a Delaware
corporation (the "COMPANY").
W I T N E S S E T H:
WHEREAS, the Board of Directors of the Company has determined that
it is fair to and in the best interests of its stockholders for Sub to merge
with and into the Company (the "MERGER") pursuant to Section 251 of the General
Corporation Law of the State of Delaware ("DGCL"), upon the terms and subject to
the conditions set forth herein;
WHEREAS, the Board of Directors of the Company has adopted
resolutions approving and declaring the advisability of the Merger, this
Agreement and the transactions and other agreements contemplated hereby, and has
resolved, upon the terms and subject to the conditions set forth herein, to
recommend that the Company's stockholders adopt this Agreement;
WHEREAS, the Board of Directors of each of Purchaser and Sub have
adopted resolutions approving and declaring the advisability of the Merger, this
Agreement and the transactions contemplated hereby;
WHEREAS, the parties have agreed (subject to the terms and
conditions of this Agreement), as soon as practicable following the approval by
the stockholders of the Company, to effect the Merger, as more fully described
herein;
WHEREAS, immediately after the execution of this Agreement and as an
inducement to Purchaser to enter into this Agreement, Purchaser and certain
stockholders of the Company will enter into a Primary Voting Agreement and a
Secondary Voting Agreement (collectively, the "VOTING AGREEMENTS") pursuant to
which such stockholders will, among other things, grant to Purchaser an
irrevocable proxy to vote in favor of the Merger, the adoption of this Agreement
and all other actions necessary to consummate the Merger, the shares of common
stock of the Company, par value $0.001 per share (the "COMMON STOCK") owned by
such stockholders as specified therein, upon the terms and subject to the
conditions specified therein;
WHEREAS, the Company and its wholly-owned subsidiary, SeraCare Life
Sciences, Inc. ("LIFE SCIENCES"), are simultaneously herewith entering into a
Master Separation and Distribution Agreement (the "SEPARATION Agreement")
pursuant to which immediately prior to the Effective Time all of the outstanding
shares of common stock of Life Sciences will be distributed to the Company's
stockholders (the "DISTRIBUTION"), and to effect the various transactions
contemplated thereby, provided that all conditions precedent to the Distribution
set forth in the Separation Agreement have been satisfied (all such transactions
being herein referred to collectively as the "SPIN-OFF");
WHEREAS, the Board of Directors of Life Sciences has adopted
resolutions approving and declaring the advisability of the Spin-Off and the
Spin-Off Agreements;
WHEREAS, for United States federal income tax purposes, it is
intended that the Distribution and the Merger be treated with respect to the
Company stockholders as an integrated transaction and that the Distribution will
be treated as a redemption of outstanding Common Stock in connection with the
complete termination of the Company stockholders' interest in the Company;
WHEREAS, the Merger will occur only after and conditioned upon the
Spin-Off; and
WHEREAS, Purchaser, Sub and the Company desire to make certain
representations, warranties, covenants and agreements in connection with the
Merger and the Spin-Off and also to prescribe various conditions to the Merger.
NOW, THEREFORE, in consideration of the foregoing premises and the
representations, warranties and agreements contained herein, the parties hereto
agree as follows:
ARTICLE I
THE SPIN-OFF AND THE MERGER
Section 1.1 THE SPIN-OFF. Concurrently with the execution of this
Agreement, the Company shall cause Life Sciences and each Person that is
intended to be a party to the agreements set forth in Section 2.1 of the
Separation Agreement (the "DISTRIBUTION ANCILLARY AGREEMENTS", and together with
the Separation Agreement, the "SPIN-OFF AGREEMENTS") to enter into the Spin-Off
Agreements and, provided that all conditions precedent to the Spin-Off set forth
in the Separation Agreement have been satisfied, on the terms and subject to the
conditions of the Spin-Off Agreements, immediately prior to the Effective Time,
the Company shall effect the Distribution in connection with the Merger and the
Company shall effect, and shall cause Life Sciences to effect, all other
transactions related to the Spin-Off.
Section 1.2 THE MERGER. Upon the terms and subject to the conditions
hereof, at the Effective Time (as hereinafter defined), Sub shall be merged with
and into the Company and the separate existence of Sub shall thereupon cease,
and the Company, as the corporation surviving the Merger (the "SURVIVING
CORPORATION"), shall by virtue of the Merger continue its corporate existence
under the laws of the State of Delaware and become a wholly-owned subsidiary of
Purchaser.
Section 1.3 EFFECTIVE TIME OF THE MERGER. The Merger shall become
effective at the date and time (the "EFFECTIVE TIME") when a certificate of
merger meeting the requirements of Section 251 of the DGCL (the "CERTIFICATE OF
MERGER") shall have been duly executed and filed in accordance with the DGCL, or
at such other time as is agreed to by Purchaser, Sub and the Company and is
specified in the Certificate of Merger in accordance with the DGCL, which
Certificate of Merger shall be filed as soon as practicable following
fulfillment of the conditions set forth in Article IX hereof.
Section 1.4 COMPANY ACTIONS. The Company hereby represents and
warrants that its Board of Directors (at a meeting duly called and held), has
(i) determined that the Merger
2
(upon the terms and subject to the conditions of this Agreement) is fair to and
in the best interests of the Company and its stockholders, (ii) resolved to
approve and declare advisable this Agreement, the Spin-Off Agreements and the
Merger, and to recommend adoption of this Agreement by the stockholders of the
Company, (iii) approved this Agreement, the Voting Agreements and the
transactions contemplated hereby and thereby for purposes of Section 203 of the
DGCL and (iv) caused the Board of Directors of Life Sciences to approve the
Spin-Off Agreements.
ARTICLE II
THE SURVIVING CORPORATION
Section 2.1 CERTIFICATE OF INCORPORATION. The Certificate of
Incorporation of the Company as in effect immediately prior to the Effective
Time shall be the Certificate of Incorporation of the Surviving Corporation,
until further amended in accordance with its terms and as provided by law.
Section 2.2 BY-LAWS. The By-laws of the Company as in effect
immediately prior to the Effective Time shall be the By-laws of the Surviving
Corporation, and thereafter may be amended in accordance with their terms and as
provided by law.
Section 2.3 BOARD OF DIRECTORS AND OFFICERS. The persons specified
in Schedule 2.3 shall be the directors of the Surviving Corporation, and the
officers of the Surviving Corporation immediately prior to the Effective Time
shall be the officers of the Surviving Corporation, in each case, until their
respective successors are duly elected and qualified.
Section 2.4 EFFECTS OF MERGER. The Merger shall have the effects set
forth in Section 259 of the DGCL.
ARTICLE III
CONVERSION OF SHARES
Section 3.1 CONVERSION OR CANCELLATION OF SHARES. At the Effective
Time, by virtue of the Merger and without any action on the part of Purchaser,
the Company, Sub or the holder of any shares of Common Stock (each issued and
outstanding share of Common Stock is referred to herein as a "Share" and
collectively as the "SHARES"):
(a) each Share outstanding immediately prior to the Effective
Time shall (except as otherwise provided in paragraph (b) of this Section 3.1 or
as provided in Section 3.3 hereof with respect to Shares as to which appraisal
rights have been demanded) be converted into the right to receive from the
Purchaser the Merger Consideration (as hereinafter defined), in cash, without
interest, upon surrender of the certificate which immediately prior to the
Effective Time represented the Share as provided in Section 3.2;
3
(b) each Share owned by Purchaser or the Company or any other
direct or indirect Subsidiary of the Company immediately prior to the Effective
Time shall be canceled and cease to exist, and no payment shall be made with
respect thereto; and
(c) each share of common stock of Sub outstanding immediately
prior to the Effective Time shall be converted into and become one share of
common stock of the Surviving Corporation with the same rights, powers and
privileges as the shares so converted.
(d) The "MERGER CONSIDERATION" shall mean the amount
determined by the formula (A+B-C) divided by (D+E) where:
"A" = $116,500,000.
"B" = The total cash paid, in the aggregate, as a result of the exercise of any
options or warrants (excluding warrants to purchase an aggregate of 3,648,599
shares of Common Stock exercised by certain warrantholders on the date hereof in
connection with the execution of the Voting Agreements) to purchase Common Stock
from June 7, 2001 until the Closing Date.
"C" = The total cash payable to option and warrant holders pursuant to Sections
3.4 and 3.5 assuming all options and warrants to purchase Common Stock
outstanding immediately prior to the Effective Time are cashed out at the
Effective Time pursuant to Sections 3.4 and 3.5 hereof.
"D" = 13,889,615
"E" = The total number of shares of Common Stock issued by the Company as a
result of the exercise of any options or warrants (excluding warrants to
purchase an aggregate of 3,648,599 shares of Common Stock exercised by certain
warrantholders on the date hereof in connection with the execution of the Voting
Agreements) to purchase Common Stock from June 7, 2001 until the Closing Date.
Section 3.2 SURRENDER AND PAYMENT. (a) Prior to the Effective Time,
Purchaser shall appoint as agent (the "EXCHANGE AGENT") a commercial bank or
trust company, reasonably acceptable to the Company and having at least
$50,000,000 in capital, surplus and undivided profits, for the purpose of
exchanging certificates which immediately prior to the Effective Time
represented Shares ("CERTIFICATES") for the Merger Consideration which holders
of Certificates are entitled to receive pursuant to this Article III.
Immediately prior to the Effective Time, Purchaser shall deposit in trust with
the Exchange Agent cash in an aggregate amount equal to the product of (i) the
number of Shares outstanding immediately prior to the Effective Time (other than
the Shares owned by Purchaser or the Company and any direct or indirect
Subsidiary of the Company, and Shares as to which appraisal rights have been
demanded) and (ii) the Merger Consideration (such amount being hereinafter
referred to as the "PAYMENT FUND"). The Payment Fund shall be invested by the
Exchange Agent as directed by Purchaser (so long as such directions do not
impair the rights of the holders of Shares) in direct obligations of the United
States of America, obligations for which the full faith and credit of the United
States of America is pledged to provide for the payment of principal and
interest, and any net earnings with respect thereto shall be paid to Purchaser
as and when requested by Purchaser. The Exchange Agent shall, pursuant to
irrevocable instructions, make the payments referred to in Section 3.2(b) out of
the Payment Fund. The Payment Fund shall not be used for any other purpose
except as
4
provided herein. Promptly after the Effective Time, Purchaser will send, or will
cause the Exchange Agent to send, to each holder of record of a Certificate or
Certificates, other than holders of Certificates which represent Shares canceled
and retired pursuant to Section 3.1(b) hereof, (i) a letter of transmittal for
use in such exchange (which shall specify that the delivery shall be effected,
and risk of loss and title with respect to the Certificates shall pass, only
upon proper delivery of the Certificates to the Exchange Agent) and (ii)
instructions for use in effecting the surrender of Certificates for payment
therefore (the "EXCHANGE INSTRUCTIONS").
(b) Each holder of Certificates that represent Shares that
have been converted into a right to receive the Merger Consideration, upon
surrender to the Exchange Agent of a Certificate or Certificates, together with
a properly completed and executed letter of transmittal covering such
Certificates and any other documents reasonably required by the Exchange
Instructions, will promptly receive the Merger Consideration payable in respect
of such Certificates as provided in this Article III, without any interest
thereon, less any required withholding of taxes, and the Certificates so
surrendered shall forthwith be canceled. After the Effective Time, and until so
surrendered, each such Certificate shall represent for all purposes only the
right to receive such Merger Consideration except as otherwise provided herein
or by applicable law.
(c) If any Certificate has been lost, stolen or destroyed,
upon the making of an affidavit of that fact by the Person claiming such
Certificate to be lost, stolen or destroyed and, if required by the Surviving
Corporation, the posting by such Person of a bond in such reasonable amount as
the Surviving Corporation may direct as indemnity against any claim that may be
made against it with respect to the loss, theft or destruction of such
Certificate, the Exchange Agent shall issue in exchange for such lost, stolen or
destroyed certificate the Merger Consideration.
(d) If any portion of the Merger Consideration is to be paid
to a Person other than the registered holder of the Shares represented by the
Certificate or Certificates surrendered in exchange therefore, it shall be a
condition to such payment that the Certificate or Certificates so surrendered
shall be properly endorsed or otherwise be in proper form for transfer and that
the Person requesting such payment shall pay to the Exchange Agent any transfer
or other taxes required as a result of such payment to a Person other than the
registered holder of such Shares or establish to the satisfaction of the
Exchange Agent that such tax has been paid or is not payable. The Exchange Agent
may make any tax withholdings required by law if not provided with the
appropriate documents. For purposes of this Agreement, "PERSON" means an
individual, a corporation, a partnership, a limited liability company, an
association, a trust or any other entity or organization, including a government
or political subdivision or any agency or instrumentality thereof.
(e) After the Effective Time, the stock transfer books of the
Company shall be closed and, thereafter, there shall be no further registration
of transfers of Shares. If, after the Effective Time, Certificates are presented
to the Surviving Corporation, they shall be canceled and exchanged for the
consideration provided for, and in accordance with the procedures set forth, in
this Article III.
5
(f) Any portion of the Payment Fund that remains unclaimed by
the holders of Certificates 270 calendar days after the Effective Time
(including, without limitation, all interest and other income received by the
Exchange Agent in respect of all funds made available to it) shall be returned
to the Surviving Corporation, upon demand, and any such holder of Certificates
who has not exchanged his or her Certificates for the Merger Consideration in
accordance with this Article III prior to that time shall thereafter look only
to the Surviving Corporation for payment of the Merger Consideration in respect
of Certificates (subject to abandoned property, escheat and other similar laws)
as general creditors thereof. Notwithstanding the foregoing, neither the
Surviving Corporation nor Purchaser shall be liable to any holder of
Certificates for an amount paid to a public official pursuant to applicable
abandoned property, escheat or other similar laws.
(g) Any portion of the Merger Consideration made available to
the Exchange Agent pursuant to this Section 3.2 to pay for Certificates
representing Shares for which appraisal rights have been demanded shall be
returned to Purchaser upon demand.
(h) All cash required to be paid hereunder for the exchange of
Certificates shall, upon payment to the holder thereof in accordance with this
Article III, be deemed to have been paid in full satisfaction of all rights
pertaining to such Certificates and the Shares represented thereby exchanged for
cash pursuant to the Merger and this Agreement.
Section 3.3 DISSENTING SHARES. Notwithstanding anything in this
Agreement to the contrary, Shares outstanding immediately prior to the Effective
Time and held by a holder who has not voted in favor of the Merger and who has
delivered a written demand for appraisal of such Shares in accordance with
Section 262 of the DGCL (the "DISSENTING SHARES") shall not be converted into
the right to receive the Merger Consideration as provided in Section 3.1 hereof,
unless and until such holder fails to perfect or effectively withdraws or
otherwise loses such holder's right to appraisal under the DGCL. Such holder of
Dissenting Shares shall be entitled to receive payment of the fair value of such
Dissenting Shares in accordance with the provisions of the DGCL, provided that
such holder complies with the provisions of Section 262 of the DGCL. At the
Effective Time, all Dissenting Shares shall be cancelled and cease to exist and
shall represent only the right to receive the fair value thereof in accordance
with the DGCL. If, after the Effective Time, any such holder fails to perfect or
effectively withdraws or otherwise loses such holder's right to appraisal, such
Dissenting Shares shall thereupon be treated as if they had been converted as of
the Effective Time into the right to receive the Merger Consideration, without
interest thereon. The Company shall give Purchaser prompt notice of any demands
received by the Company for appraisal of Shares, and, prior to the Effective
Time, Purchaser shall have the right to participate in all negotiations and
proceedings with respect to such demands. Prior to the Effective Time, the
Company shall not, except with the prior written consent of Purchaser, make any
payment with respect to, or settle or offer to settle, any such demands.
Section 3.4 STOCK OPTIONS. (a) Immediately prior to the Distribution
each holder of a compensatory option to purchase Common Stock (an "OPTION") then
outstanding shall be issued an option to purchase a number of shares of the
common stock of Life Sciences equal to the number of shares of Common Stock for
which such Option was, immediately prior to the Distribution, outstanding
(whether or not then exercisable), with an exercise price equal to
6
the Calculated Exercise Price. At the Effective Time, all Options outstanding
immediately prior to the Effective Time, whether or not then exercisable, shall
be canceled and each holder of an Option will be entitled to receive from the
Surviving Corporation for each share of Common Stock subject to an Option, an
amount in cash equal to the excess, if any, of the Merger Consideration over the
Adjusted Exercise Price of such Option, without interest. All amounts payable
pursuant to this Section 3.4 shall be subject to all applicable withholding of
taxes. The Company shall use commercially reasonable efforts to effectuate the
foregoing, including using commercially reasonable efforts to obtain all
necessary consents of the holders of Options or to effect amendments of Options
and taking actions necessary to approve the disposition of the options to the
extent necessary to exempt such dispositions and acquisitions under Rule 16b-3
of the Securities Exchange Act of 1934, as amended (the "EXCHANGE ACT").
(b) The "CALCULATED EXERCISE PRICE" shall be determined, with
respect to each Option or Warrant, by the following formula: A multiplied by (B
divided by (B+C)), where:
"A" = The exercise price of the applicable Option or Warrant immediately prior
to the Distribution.
"B" = The fair market value of Life Sciences as determined by Xxxxxxxx Xxxxx
Xxxxxx and Xxxxx or another independent third-party appraisal firm designated by
the Company and reasonably consented to by Purchaser whose determination of such
fair market value shall be conclusive.
"C" = $116,500,000.
(c) The "ADJUSTED EXERCISE PRICE" shall be determined, with
respect to each Option or Warrant, as applicable, by subtracting the Calculated
Exercise Price for such Option or Warrant from the exercise price of such Option
or Warrant immediately prior to the Distribution.
Section 3.5 WARRANTS. Immediately prior to the Distribution, in
connection with the Merger, each holder of a non-compensatory warrant to
purchase Common Stock (a "WARRANT") then outstanding shall be issued a warrant
to purchase a number of shares of the common stock of Life Sciences equal to the
number of shares of Common Stock for which such Warrant was, immediately prior
to the Distribution, outstanding (whether or not then exercisable), with an
exercise price equal to the Calculated Exercise Price. Except as set forth in
Section 3.5 of the Company Disclosure Letter (as hereinafter defined), at the
Effective Time all Warrants outstanding immediately prior to the Effective Time,
whether or not then exercisable, shall be canceled and each holder of a Warrant
will be entitled to receive from the Surviving Corporation, for each share of
Common Stock subject to a Warrant, an amount in cash equal to the excess, if
any, of the Merger Consideration over the Adjusted Exercise Price of such
Warrant, without interest. All amounts payable pursuant to this Section 3.5
shall be subject to all applicable withholding of taxes. The Company shall use
commercially reasonable efforts to effectuate the foregoing, including using
commercially reasonable efforts to obtain all necessary consents of the holders
of Warrants or to effect amendments of Warrants.
7
Section 3.6 STOCKHOLDERS MEETING. Subject to the terms and
conditions contained herein, the Company shall, as promptly as practicable,
convene a meeting of its stockholders (the "SPECIAL MEETING") to consider and
vote upon adoption of this Agreement. Subject to its fiduciary duties, the Board
of Directors of the Company shall recommend such adoption and the Company shall
use its commercially reasonable efforts to obtain adoption of this Agreement by
its stockholders.
Section 3.7 CLOSING. The closing of the transactions contemplated by
this Agreement (the "CLOSING") shall take place at the offices of Proskauer Rose
LLP, 0000 Xxxxxxxx, Xxx Xxxx, Xxx Xxxx 00000, at 10:00 a.m. local time on the
first business day after the day on which the last of the conditions set forth
in Article IX (other than those that can only be fulfilled at the Effective
Time) is fulfilled or waived or at such other time and place as Purchaser and
the Company shall agree in writing. The date on which the Closing occurs is
referred to herein as the "CLOSING DATE."
Section 3.8 TRANSFER TAXES. Purchaser and the Company shall
cooperate in the preparation, execution and filing of all returns, applications
or other documents regarding any real property transfer, stamp, recording,
documentary or other taxes and any other fees and similar taxes which become
payable in connection with the Merger other than transfer or stamp taxes payable
in respect of transfers referenced in Section 3.2(d).
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF PURCHASER
Purchaser represents and warrants to the Company as follows:
Section 4.1 ORGANIZATION, STANDING AND POWER. Purchaser is a
corporation duly organized, validly existing and in good standing under the laws
of Spain and has all requisite corporate power and corporate authority to carry
on its business as now being conducted.
Section 4.2 AUTHORITY; NON-CONTRAVENTION. Purchaser has all
requisite corporate power and corporate authority to enter into this Agreement
and to consummate the transactions contemplated hereby. The execution and
delivery of this Agreement by Purchaser and the consummation by Purchaser of the
transactions contemplated hereby have been duly authorized by all necessary
corporate action on the part of Purchaser. This Agreement has been duly executed
and delivered by Purchaser and (assuming the valid authorization, execution and
delivery of this Agreement by the Company) constitutes a valid and binding
obligation of Purchaser enforceable against Purchaser in accordance with its
terms. The execution and delivery of this Agreement does not, and the
consummation of the transactions contemplated hereby and compliance with the
provisions hereof will not, conflict with, or result in any violation of, or
default (with or without notice or lapse of time, or both) under, or give rise
to a right of termination, cancellation or acceleration of any obligation or to
the loss of a material benefit under, or result in the creation of any lien,
security interest, charge or encumbrance upon any of the properties or assets of
Purchaser or any of its Subsidiaries under, any provision of (i) the certificate
of incorporation, by-laws and other organizational documents of Purchaser and
8
any of its Subsidiaries, (ii) any loan or credit agreement, note, bond,
mortgage, indenture, lease or other agreement, instrument, permit, concession,
franchise or license applicable to Purchaser or any of its Subsidiaries or (iii)
any judgment, order, decree, statute, law, ordinance, rule or regulation
applicable to Purchaser or any of its Subsidiaries or any of their respective
properties or assets, other than, in the case of clause (ii) or (iii), any such
conflicts, violations, defaults, rights, liens, security interests, charges or
encumbrances that, individually or in the aggregate, would not have a Material
Adverse Effect (as hereinafter defined) on Purchaser, materially impair the
ability of Purchaser to perform its obligations hereunder or prevent the
consummation of any of the transactions contemplated hereby. No filing or
registration with, or authorization, consent or approval of, any domestic
(federal, state or local), foreign or supranational court, commission,
government, governmental body, regulatory or administrative agency, authority or
tribunal (a "GOVERNMENTAL ENTITY") is required by or with respect to Purchaser
or any of its Subsidiaries in connection with the execution and delivery of this
Agreement by Purchaser or is necessary for the consummation of the Merger and
the other transactions contemplated by this Agreement, except for (i) in
compliance with the Exchange Act, (ii) the filing of the Certificate of Merger
with the Secretary of State of the State of Delaware and appropriate documents
with the relevant authorities of other states in which the Company is qualified
to do business, (iii) compliance with any applicable requirements of the
Internal Revenue Service or any state taxing authority, (iv) compliance with any
applicable foreign or state securities or blue sky laws (collectively, "BLUE SKY
LAWS"), (v) filings required by the Xxxx-Xxxxx-Xxxxxx Antitrust Improvements Act
of 1976, as amended (the "HSR Act") and (vi) such other consents, orders,
authorizations, registrations, declarations and filings of non-Governmental
Entities the failure of which to be obtained or made would not, individually or
in the aggregate, have a Material Adverse Effect on Purchaser, materially impair
the ability of Purchaser to perform its obligations hereunder or prevent the
consummation of any of the transactions contemplated hereby. For purposes of
this Agreement, "MATERIAL ADVERSE CHANGE" or "MATERIAL ADVERSE EFFECT" means,
when used with respect to Purchaser, Sub, the Company, or the Company (after
giving effect to the Spin-Off), as the case may be, any change or effect, either
individually or in the aggregate, that is or is reasonably expected to be
materially adverse to the business, assets, liabilities, financial condition or
results of operations of (i) Purchaser and its Subsidiaries, taken as a whole,
(ii) Sub, taken as a whole; (iii) the Company and its Subsidiaries, taken as a
whole; or (iv) the Company and its Subsidiaries, taken as a whole (after giving
effect to the Spin-Off as if the Spin-Off had occurred prior to the date or
period in question), except to the extent that such change or effect is
attributable to or results from changes in general economic conditions or
securities markets in general, general changes in the industries in which the
Company and its Subsidiaries operate (including, without limitation, the
adoption or implementation of regulatory changes) or the effect of the public
announcement or pendency of the transactions contemplated hereby.
Section 4.3 FINANCING. Purchaser has executed a financing commitment
letter in respect of the Merger (the "COMMITMENT LETTER"). Assuming full funding
under the Commitment Letter, Purchaser will have sufficient cash funds to
consummate the transactions contemplated hereby, including, without limitation,
the payment of (i) the aggregate Merger Consideration payable in respect of each
Share (less the cash received by the Company, if any, from the exercise of any
Options or Warrants after the date hereof), (ii) the total cash payable to
Option and Warrant holders pursuant to Sections 3.4 and 3.5 and (iii) related
fees and expenses (the "FINANCING"). Purchaser has delivered a copy of the
Commitment Letter to the Company. To the knowledge of the Purchaser, the
Commitment Letter is in full force and effect and there is
9
no fact, occurrence or condition that would cause the Commitment Letter to be
terminated or ineffective or any of the conditions contained therein not to be
met.
Section 4.4 BROKERS. No broker, investment banker or other person,
other than Deutsche Bank Investment Banking, the fees and expenses of which will
be paid by Purchaser, is entitled to any broker's, finder's or other similar fee
or commission in connection with the transactions contemplated by this Agreement
based upon arrangements made by or on behalf of the Purchaser or Sub.
Section 4.5 SHARE OWNERSHIP. Without giving effect to Purchaser's or
Sub's entry into this Agreement and the Voting Agreements and the consummation
of the transactions contemplated hereunder and thereunder, neither Purchaser nor
Sub is an "owner" (as such term is defined in Section 203(c)(9) of the DGCL) of
any Shares.
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to Purchaser and Sub as follows:
Section 5.1 ORGANIZATION, STANDING AND POWER. The Company and each
of its Subsidiaries is a corporation duly organized, validly existing and in
good standing under the laws of the jurisdiction in which it is incorporated and
has the requisite power and authority to carry on their respective businesses as
now being conducted. The Company and each of its Subsidiaries is duly qualified
to do business, and is in good standing, in each jurisdiction where the
character of its respective properties owned or held under lease or the nature
of its respective activities makes such qualification necessary, except where
the failure to be so qualified would not, individually or in the aggregate, have
a Material Adverse Effect on the Company.
Section 5.2 CAPITAL STRUCTURE. The authorized capital stock of the
Company consists of 25,000,000 shares of Common Stock, and 25,000,000 shares of
preferred stock of the Company, par value $0.001 per share (the "PREFERRED
STOCK"), issuable in one or more series, of which 43,600 shares of Preferred
Stock have been designated. At the close of business on June 6, 2001, (i)
9,741,016 shares of Common Stock were issued and outstanding and (ii) 11,581,107
shares of Common Stock were reserved for issuance upon the exercise of
outstanding options, warrants, convertible securities and stock rights in the
Company. At the close of business on June 6, 2001, 22,500 shares of Series C
Convertible Preferred Stock were issued and outstanding. All outstanding shares
of capital stock of the Company are validly issued, fully paid and nonassessable
and not subject to preemptive rights. As of June 6, 2001, the Company had
granted options to acquire an aggregate of 455,002 shares of Common Stock at
$3.25 per share, pursuant to the Company's 1998 Stock Incentive Plan (the "STOCK
PLAN") and options to acquire an aggregate of 100,000 shares of Common Stock at
$3.25 per share, pursuant to the Company's 1997 Informal Stock Compensation
Plan. Except as otherwise set forth in this Section 5.2 or in the Company
Disclosure Letter (the "COMPANY DISCLOSURE LETTER"), in which the Company shall
make the disclosures required by or referred to in this Agreement which shall be
listed under headings corresponding to the section references in this Agreement,
there are no
10
options, warrants, rights, commitments, agreements, arrangements or undertakings
of any kind to which the Company is a party or by which it is bound obligating
the Company to issue, deliver or sell, or cause to be issued, delivered or sold,
additional shares of capital stock or other voting securities of the Company or
any of its Subsidiaries, including any securities pursuant to which rights to
acquire capital stock became exercisable only after a change of control of the
Company or any of its Subsidiaries or upon the acquisition of a specified amount
of the Common Stock or voting power of the Company or any of its Subsidiaries.
Except as set forth in the Company Disclosure Letter, since February 28, 2001,
no shares of the capital stock of the Company or any of its Subsidiaries have
been issued other than pursuant to the exercise of Company stock options and
warrants already in existence and outstanding on such date or conversion of
Series C Convertible Preferred Stock, and neither the Company nor any of its
Subsidiaries has granted any stock options, warrants or other rights to acquire
any capital stock of the Company or any of its Subsidiaries. Except as specified
in the Company Disclosure Letter or as contemplated herein, there are no
agreements, arrangements or other understandings in respect of the right to vote
any shares of capital stock of the Company, there are no securities issued by
the Company or agreements, arrangements or other understandings to which the
Company is a party giving any person any right to acquire equity securities of
the Surviving Corporation at or following the Effective Time and all securities,
agreements, arrangements and understandings relating to the right to acquire
equity securities of the Company (whether pursuant to the exercise of options,
warrants or otherwise) provide that, at and following the Effective Time, such
right shall entitle the holder thereof to receive the consideration he would
have received in the Merger had he exercised his right immediately before the
Effective Time. The Company Disclosure Letter sets forth a complete list of all
options, warrants, convertible or exchangeable securities, or other rights to
purchase shares of capital stock or other securities of the Company or any
Subsidiary. The Company Disclosure Letter contains a true and correct copy of
the stock register provided to the Company by its transfer agent as of March 31,
2001.
Section 5.3 SUBSIDIARIES. Except as set forth in the Company
Disclosure Letter, (i) the Company owns, directly or indirectly through a
Subsidiary, all of the outstanding shares of capital stock (or other ownership
interests having by their terms ordinary voting power to elect directors or
others performing similar functions with respect to such Subsidiary) of each of
the Company's Subsidiaries and (ii) each of the outstanding shares of capital
stock of each of the Company's Subsidiaries is duly authorized, validly issued,
fully paid and nonassessable, and is owned, directly or indirectly, by the
Company free and clear of all liens, pledges, security interests, claims or
other encumbrances. There are no agreements, arrangements or other
understandings in respect of the right to vote any shares of capital stock of
any Subsidiary. The Company Disclosure Letter sets forth for each Subsidiary of
the Company: (i) its name and jurisdiction of incorporation or organization;
(ii) its authorized capital stock or share capital; (iii) the number of issued
and outstanding shares of capital stock or share capital; and (iv) the holder or
holders of such shares. Except for interests in the Company's Subsidiaries or as
set forth in the Company Disclosure Letter, neither the Company nor any of its
Subsidiaries owns directly or indirectly any interest or investment (whether
equity or debt) in any corporation, partnership, joint venture, business, trust
or other entity.
Section 5.4 AUTHORITY; NON-CONTRAVENTION. The Board of Directors of
the Company has declared the Merger and the adoption of this Agreement
advisable, fair to and in the best interests of the Company and its
stockholders, and the Company has all requisite
11
corporate power and corporate authority to enter into this Agreement and,
subject to the adoption of this Agreement by the stockholders of the Company, to
consummate the transactions contemplated hereby. The Company has caused the
Board of Directors of Life Sciences to approve the Spin-Off and the Spin-Off
Agreements. The execution and delivery of this Agreement by the Company and the
consummation by the Company of the transactions contemplated hereby have been
duly authorized by all necessary corporate action on the part of the Company,
subject to the adoption of this Agreement by the stockholders of the Company.
The only votes of the holders of any class or series of Company capital stock
necessary to adopt this Agreement are the affirmative votes of the holders of a
majority of the outstanding shares of Common Stock. This Agreement has been duly
executed and delivered by the Company and (assuming the valid authorization,
execution and delivery of this Agreement by Purchaser and Sub, as applicable,
and adoption of this Agreement by the stockholders of the Company) constitutes a
valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except as the enforceability thereof may be limited
by creditors' rights generally or by general principles of equity. Except as set
forth in the Company Disclosure Letter, the execution and delivery of this
Agreement does not, and the consummation of the transactions contemplated hereby
and compliance with the provisions hereof will not, conflict with, or result in
any violation of, or default (with or without notice or lapse of time, or both)
under, or give rise to a right of termination, cancellation or acceleration of
any obligation or to the loss of a material benefit under, or result in the
creation of any lien, security interest, charge or encumbrance upon any of the
properties or assets of the Company or any of its Subsidiaries under, any
provision of (i) the certificate of incorporation, by-laws or other
organizational documents of the Company or any of its Subsidiaries (true and
complete copies of which as of the date hereof have been delivered to
Purchaser), (ii) any loan or credit agreement, note, bond, mortgage, indenture,
lease, other agreement or instrument, permit, concession, franchise or license
applicable to the Company or any of its Subsidiaries or (iii) any judgment,
order, decree, statute, law, ordinance, rule or regulation applicable to the
Company or any of its Subsidiaries or any of their respective properties or
assets; except in the case of clause (ii) or (iii) above for such conflicts,
violations, defaults, rights, losses or liens as would not, either individually
or in the aggregate, result in a Material Adverse Effect on the Company. No
filing or registration with, or authorization, consent or approval of, any
Governmental Entity is required by or with respect to the Company or any of its
Subsidiaries in connection with the execution and delivery of this Agreement by
the Company or the consummation by the Company of the transactions contemplated
hereby, except for (i) compliance with the provisions of the Securities Act of
1933, as amended (the "SECURITIES ACT"), (ii) compliance with the provisions of
the Exchange Act, (iii) the filing of the Certificate of Merger with the
Secretary of State of the State of Delaware and appropriate documents with the
relevant authorities of other states in which the Company is qualified to do
business, (iv) compliance with any applicable requirements of the Internal
Revenue Service or any state taxing authority, (v) compliance with any
applicable Blue Sky Laws, (vi) filings required by the HSR Act, (vii) those
matters including but not limited to, regulatory consents, approvals and
waivers, specified in the Company Disclosure Letter, and (viii) such other
consents, orders, authorizations, registrations, declarations and filings of
non-Governmental Entities the failure of which to be obtained or made would not,
individually or in the aggregate, have a Material Adverse Effect on the Company,
materially impair the ability of the Company and its Subsidiaries to perform its
obligations hereunder or prevent the consummation of any of the transactions
contemplated hereby.
12
Section 5.5 SEC DOCUMENTS; FINANCIAL STATEMENTS. (a) The Company has
filed all documents with the Securities and Exchange Commission (the "SEC")
required to be filed by the Company under the Securities Act or the Exchange Act
since May 27, 1999 (the "COMPANY SEC DOCUMENTS"). As of their respective dates,
the Company SEC Documents complied in all material respects with the
requirements of the Securities Act or the Exchange Act, as the case may be, and
none of the Company SEC Documents contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or
necessary in order to make the statements made therein, in light of the
circumstances under which they were made, not misleading. The Company has made
available to Purchaser each registration statement, report, proxy statement or
information statement prepared by it and filed with the SEC since May 27, 1999,
in the form, including any exhibits or amendments thereto, filed with the SEC
(collectively, the "COMPANY REPORTS"). The financial statements of the Company
included in the Company SEC Documents and the Company Reports (the "COMPANY
FINANCIAL STATEMENTS") as of their respective dates complied as to form in all
material respects with applicable accounting requirements and the published
rules and regulations of the SEC with respect thereto, were prepared in
accordance with generally accepted accounting principles (except, in the case of
unaudited statements, as permitted by Form 10-Q or 10-QSB of the SEC) applied on
a consistent basis during the periods involved (except as may be indicated
therein or in the notes thereto) and fairly present in all material respects the
financial position of the Company as at the dates thereof and the results of its
operations and changes in financial position for the periods then ended
(subject, in the case of unaudited statements, to normal year-end audit
adjustments and to any other adjustments set forth therein). The audited
consolidated balance sheet of the Company and its Subsidiaries as of February
29, 2000 is sometimes referred to herein as the "REFERENCE BALANCE SHEET".
Notwithstanding anything herein to the contrary, the failure of the Company to
have filed with the SEC any agreement referred to in the Company Disclosure
Letter as an exhibit to a Company Report shall not be deemed a breach of the
Company's representations contained in this Section 5.5(a). The Company has
heretofore made available or promptly shall make available to Purchaser a
complete and correct copy of any amendments or modifications, which have not yet
been filed with the SEC, to agreements, documents or other instruments which
previously have been filed with the SEC pursuant to the Securities Act or the
Exchange Act.
(b) Section 5.5(b) of the Company Disclosure Letter contains
the unaudited pro forma consolidated balance sheets of the Company and its
Subsidiaries as of February 28, 1999, February 29, 2000 and February 28, 2001
(each, a "PRO FORMA BALANCE SHEET"), and the unaudited pro forma consolidated
statements of income of the Company and its Subsidiaries for the years ended
February 28, 1999, February 29, 2000 and February 28, 2001 (each, a "PRO FORMA
INCOME STATEMENT"). Such statements present information on the basis of the
assumptions set forth therein as of or for the periods ending on February 28,
1999, February 29, 2000 and February 28, 2001, as applicable. Such statements
are based on, and should be read in conjunction with, the historical
consolidated financial statements included in the Company SEC Documents. Each
Pro Forma Balance Sheet fairly presents in all material respects the
consolidated financial position of the Company and its Subsidiaries, excluding
the financial position of Life Sciences and Consolidated Technologies, Inc., as
applicable, as of its respective date on the basis of the assumptions set forth
therein. Each Pro Forma Income Statement fairly presents in all material
respects the results of operations of the Company and its Subsidiaries,
13
excluding the results of operations of Life Sciences and Consolidated
Technologies, Inc., as applicable, for the periods set forth therein on the
basis of the assumptions set forth therein.
Section 5.6 BOOKS AND RECORDS. (a) The Company and its Subsidiaries
maintain a system of internal accounting controls sufficient to provide
reasonable assurance that transactions are executed with its management's
authorizations, and all material transactions are recorded as are reasonably
required to permit preparation of the Company Financial Statements in accordance
with GAAP and to maintain accountability for all material assets.
(b) The books of account, minute books, and to the Company's
knowledge, the stock record books and other records of the Company and its
Subsidiaries (the "BOOKS AND RECORDS") accurately and fairly reflect, in all
material respects, in reasonable detail, the matters reflected therein. The
Books and Records have been made available to Purchaser for its inspection.
(c) Neither the Company nor any of its Subsidiaries has
engaged in any monetary transaction, maintained any bank account or used any
corporate funds except for monetary transactions, bank accounts or funds which
have been and are reflected in the Books and Records or such as are not material
to the results of operations or financial condition of the Company.
Section 5.7 ABSENCE OF UNDISCLOSED LIABILITIES. Except as set forth
in the Company Disclosure Letter, the Company SEC Documents or the Company
Reports, to the Company's knowledge, neither the Company nor any of its
Subsidiaries has any liability or obligation of any nature (whether accrued,
absolute, contingent or otherwise), except for liabilities and obligations
incurred in the ordinary course of business consistent with past practice.
Section 5.8 ACCOUNTS RECEIVABLE. All third party accounts receivable
of the Company and its Subsidiaries that are reflected in the Company Financial
Statements since the date of the Reference Balance Sheet (collectively, the
"ACCOUNTS RECEIVABLE") arose from sales actually made or services actually
performed to or for (as applicable) Persons other than the Company and any of
its Subsidiaries.
Section 5.9 INVENTORY. The Company Disclosure Letter sets forth,
subject to the assumptions described therein, the consolidated total source
plasma inventory of the Company and its Subsidiaries as of February 28, 2001
(the "PRO FORMA SOURCE PLASMA INVENTORY"). The Pro Forma Source Plasma Inventory
excludes the inventory of Life Sciences as of February 28, 2001 and was
determined on the basis of the assumptions set forth in the Pro Forma Balance
Sheet for the fiscal year ended February 28, 2001. Subject to the assumptions
described in the Company Disclosure Letter, the Pro Forma Source Plasma
Inventory consists of a quality usable by and salable to the blood plasma
fractionation industry, except where the failure of such inventory to consist of
such quality to be usable by and salable to the blood plasma fractionation
industry would not have a Material Adverse Effect on the Company.
Section 5.10 ABSENCE OF CERTAIN CHANGES OR EVENTS. Since the date of
the Reference Balance Sheet, except (i) as disclosed on the Company Disclosure
Letter, the
14
Company SEC Documents or the Company Reports, (ii) as permitted pursuant to
Section 7.1 hereof, (iii) as expressly contemplated by the Spin-Off Agreements,
and (iv) as the changes or events enumerated in this Section 5.10 would not,
either individually or in the aggregate, have a Material Adverse Effect on the
Company, the Company and each of its Subsidiaries has operated its business only
in the ordinary course consistent with past practice, and there has not been
any:
(a) Material Adverse Change in respect of the Company;
(b) acquisition by the Company or any of its Subsidiaries by
merger, consolidation or purchase (including by purchase of all or substantially
all of the assets, or any material assets or business), except for acquisitions
of assets made in the ordinary course of business consistent with past practice;
(c) acquisition, directly or indirectly, by the Company or any
of its Subsidiaries, by redemption or otherwise, of any shares of capital stock
of the Company or any of its Subsidiaries;
(d) declaration or payment of any dividends on any shares of
capital stock of the Company or any of its Subsidiaries;
(e) (i) increase in the compensation payable or to become
payable by the Company or its Subsidiaries to any of their respective officers,
employees or agents (collectively, "PERSONNEL") whose total compensation for
services rendered to the Company or its Subsidiaries is currently at an annual
rate of more than $75,000 (except for increases in the ordinary course of
business consistent with past practice), (ii) bonus, incentive compensation,
service award or other like benefit, which are set forth in the Company
Disclosure Letter, and which have been granted, made or accrued, contingently or
otherwise, for or to the credit of any of the Personnel (except for bonuses,
incentive compensation, service awards or other like benefits granted, made or
accrued in the ordinary course of business consistent with past practice), (iii)
employee welfare, pension, retirement, profit-sharing, insurance or similar
payment or arrangement made or agreed to by the Company or any of its
Subsidiaries for any Personnel except pursuant to the existing plans and
arrangements described in the Company Disclosure Letter or (iv) any agreement,
arrangement or transaction with any of its directors, officers, employees or
shareholders (or with any beneficiary or with a member of such persons'
"immediate family" as such term is defined in the instructions to paragraph (a)
of Item 404 of Regulation S-K of the regulations of the SEC (hereinafter, an
"IMMEDIATE FAMILY MEMBER")), including, without limitation, any retention,
change in control or non-competition agreement or arrangement;
(f) addition to or modification of any Company Benefit Plan
affecting Personnel other than: (i) contributions made in accordance with the
normal practices of the Company and its Subsidiaries or (ii) the extension of
coverage to other Personnel who became eligible after the date of the Reference
Balance Sheet;
(g) sale (other than sales of inventory in the ordinary course
of business), lease, assignment, transfer or other disposition of any material
assets or properties of the Company or its Subsidiaries other than in the
ordinary course;
15
(h) cancellation of any indebtedness or waiver of any claims
or rights of substantial value to the Company and its Subsidiaries, taken as a
whole, or mortgage, pledge or imposition of any material Liens on any material
asset or property of the Company or any of its Subsidiaries;
(i) entry into, amendment, cancellation or termination by the
Company or any of its Subsidiaries of any Contract, license or other instrument
material to the Company and its Subsidiaries, taken as a whole;
(j) capital expenditure or the execution of any lease or any
incurring of liability therefore by the Company or any of its Subsidiaries,
involving payments in excess of $250,000 individually or $500,000 in the
aggregate, except in the ordinary course consistent with past practices;
(k) failure to operate the business of the Company and its
Subsidiaries in the ordinary course so as to use reasonable efforts to preserve
the business intact, to keep available the services of the Personnel, and to
preserve the goodwill of the suppliers, customers and others having business
relations with the Company or its Subsidiaries;
(l) change in accounting methods or practices by the Company
or its Subsidiaries;
(m) material revaluation by the Company or any of its
Subsidiaries of any of their respective assets, including without limitation,
writing off notes, Accounts Receivable or inventory;
(n) damage, destruction or loss (whether or not covered by
insurance) of any asset or property of the Company and its Subsidiaries;
(o) any indebtedness incurred by the Company or any of its
Subsidiaries for borrowed money or any commitment to borrow money entered into
by the Company or any of its Subsidiaries, or any loans made or agreed to be
made by the Company or any of its Subsidiaries, except for indebtedness,
commitments or loans not exceeding $250,000 in the aggregate;
(p) any assets or properties of the Company or any of its
Subsidiaries (whether tangible or intangible) permitted or allowed to be
subjected to any Lien, other than (i) Permitted Liens and (ii) Liens that will
be released at or prior to the Closing;
(q) any material changes in the customary methods of
operations of the business of the Company or its Subsidiaries, including,
without limitation, practices and policies relating to the process of collecting
plasma, manufacturing, purchasing, inventories, marketing, selling and pricing;
(r) issuances by the Company or any of its Subsidiaries of any
purchase orders or any other agreement to make any purchases of supplies
involving exchanges in value in excess of $250,000 individually;
16
(s) discounting by the Company or any of its Subsidiaries of
the Accounts Receivable;
(t) any material Permit that was issued or relates to the
Company or its Subsidiaries that was allowed to lapse or terminate or failure to
renew any such Permit or any insurance policy that is scheduled to terminate or
expire within 60 calendar days of the Closing Date;
(u) termination, discontinuation, closing or disposition of
any office, plant, facility or other material business operation by the Company
or any of its Subsidiaries, or any lay off of employees by the Company or any of
its Subsidiaries, or implementation of any early retirement, separation or
program providing early retirement window benefits by the Company or any of its
Subsidiaries or announcement or planning of any such action or program by the
Company or any of its Subsidiaries for the future;
(v) any express or deemed settlement or compromise by the
Company or any of its Subsidiaries of any material liability with respect to
Taxes;
(w) amendment or restatement of the certificate of
incorporation or the by-laws (or other organizational documents) of the Company
or any Subsidiary;
(x) to the Company's knowledge, any material action, suit,
claim or pending or threatened investigation by any Governmental Entity or
Industry Compliance Entity (as hereinafter defined) against the Company or its
Subsidiaries or any of their officers or directors; and
(y) agreement, whether oral or written, by the Company or any
of its Subsidiaries to do any of the foregoing.
Section 5.11 LITIGATION. Except as set forth in the Company
Disclosure Letter, the Company Reports or the Company SEC Documents, there are
no actions, suits, claims or proceedings pending against the Company or any of
its Subsidiaries or, to the knowledge of the Company or any of its Subsidiaries,
threatened against the Company or any of its Subsidiaries, at law or in equity,
or before or by any federal or state commission, board, bureau, agency,
regulatory or administrative instrumentality or other Governmental Entity or any
arbitrator or arbitration tribunal that, if adversely determined, would have a
Material Adverse Effect on the Company. To the knowledge of the Company or any
of its Subsidiaries, no development has occurred with respect to any pending or
threatened action, suit or proceeding that would prevent the consummation of the
transactions contemplated hereby.
Section 5.12 COMPLIANCE WITH LAW. (a) Except as set forth in the
Company Disclosure Letter, the Company Reports or the Company SEC Documents, to
the knowledge of the Company and its Subsidiaries, neither the Company nor any
of its Subsidiaries is the subject of any pending or threatened investigation,
consent decree, consent agreement, corporate integrity agreement, warning letter
or notice, nor since May 27, 1999 has any investigation, or prosecution or other
action been threatened by any Governmental Entity or Industry Compliance Entity
(as defined below) regarding non-compliance with any law or regulation. As used
in this Agreement, the term "COMPANY PRODUCTS AND SERVICES" means and includes:
(i) any of the blood
17
plasma products, source plasma products, therapeutic products, plasma-based or
other diagnostic products, and any other similar or related products, materials
(bulk or otherwise) or substances, and including any and all applicable products
discussed in the Company SEC Documents, which have been in the past or currently
are being collected, procured or otherwise obtained, researched, manufactured,
developed, processed, packed, packaged, stored, transported, distributed,
marketed or sold by the Company or any of its Subsidiaries worldwide and (ii)
any services, including but not limited to any distribution operations,
laboratory or consulting services, rendered by the Company or its Subsidiaries
worldwide. The Company Disclosure Letter sets forth a complete list of all
material Company Products and Services.
(b) Except as set forth in the Company Disclosure Letter, the
Company Reports or the Company SEC Documents, the Company and each of its
Subsidiaries has obtained, and maintains in force, all licenses, permits,
franchises, certificates of authority, orders and waivers ("PERMITS") required
from or by any Governmental Entity including without limitation the U.S. Food
and Drug Administration, the U.S. Occupational Safety and Health Administration
("OSHA"), the Center for Biologics Evaluation and Research, the American Blood
Resources Association, the Quality Plasma Program, and any comparable U.S. state
or foreign agency or entity or industry association (collectively, the "INDUSTRY
COMPLIANCE ENTITIES") to operate its respective businesses, including producing
or rendering Company Products and Services, as the case may be, and to occupy,
operate and use any buildings, improvements, fixtures and equipment owned or
leased in connection with the production or rendering of the Company Products
and Services, as the case may be, at all locations or facilities of the Company
and its Subsidiaries except where the failure to obtain and maintain any such
Permit would not, either individually or in the aggregate, have a Material
Adverse Effect on the Company, and all such Permits are valid and in full force
and effect except where the failure to be valid and in full force and effect
would not, either individually or in the aggregate, have a Material Adverse
Effect on the Company. Except as specified in the Company Disclosure Letter, all
of the Permits referenced in the foregoing sentence have been issued in the name
of the Company or the applicable Subsidiary having an ownership, leasehold,
management or operational interest in the facilities referenced therein, except
where the failure of a Permit to have been issued in the name of the Company or
the applicable Subsidiary would not, either individually or in the aggregate,
have a Material Adverse Effect. All licenses issued by the U.S. Food and Drug
Administration with respect to the plasma centers operated by the Company and
its Subsidiaries shall remain valid and in full force and effect upon
consummation of the transactions expressly contemplated by this Agreement
without the necessity of any action by the Company. Since May 27, 1999, no
Permits of the Company or any Subsidiary have been suspended, canceled or
terminated and, to the knowledge of the Company and its Subsidiaries, no
suspension, cancellation or termination of any such Permits is threatened or
imminent, except where the suspension, cancellation or termination of a Permit
would not, either individually or in the aggregate, have a Material Adverse
Effect on the Company. To the Company's knowledge, each employee of the Company
and each of its Subsidiaries has obtained and maintains in force, all licenses,
permits or similar authorizations required from or by any Governmental Entity,
Industry Compliance Entity or Customer to authorize such employee to perform his
or her duties on behalf of the Company and its Subsidiaries.
(c) With respect to all Company Properties and the production
or rendering of the Company Products and Services, as the case may be, to the
Company's
18
knowledge, except as set forth in the Company Disclosure Letter, the Company and
each of its Subsidiaries is in compliance in all material respects with (i) 21
C.F.R. Parts 207, 211, 606 and 640; and (ii) all legal requirements,
regulations, licenses, permits, export regulations and licenses, and
notifications required by any Governmental Entity, Industry Compliance Entity or
Customer including, without limitation, the Clinical Laboratory Improvements Act
of 1988, as amended, and all applicable regulations promulgated thereunder, the
Needlestick Safety and Prevention Act of 2000 (where applicable) and all legal
requirements, regulations, rules and standards promulgated by OSHA, including
without limitation the Bloodborne Pathogens standard; except, with respect to
clauses (i) and (ii) above, where such failure to be in compliance would not,
either individually or in the aggregate, have a Material Adverse Effect on the
Company.
(d) Except as set forth in the Company Disclosure Letter, (i)
no Company Products and Services have been recalled, withdrawn, suspended or
discontinued (other than voluntary discontinuance for legitimate business
reasons) by the Company or any its Subsidiaries in the United States and outside
the United States during the period commencing on the date of the Reference
Balance Sheet and ending on the date hereof, except where such recall,
withdrawal, suspension or discontinuation would not, either individually or in
the aggregate, have a Material Adverse Effect on the Company, and (ii) no
proceedings in the United States or outside of the United States of which the
Company has knowledge (whether completed or pending) seeking the recall,
withdrawal, suspension or seizure of any Company Products and Services are
pending or threatened against the Company or any of its Subsidiaries, nor to the
Company's knowledge have any such proceedings been pending or threatened at any
time during the period commencing on the date of the Reference Balance Sheet and
ending on the date hereof, except where such pending or threatened proceeding
would not, either individually or in the aggregate, have a Material Adverse
Effect on the Company.
(e) To the Company's knowledge, the Company and each
Subsidiary has used reasonable commercial efforts to establish and implement
quality assurance and compliance programs, including the hiring of appropriate
Personnel, designed to insure that the Company and each Subsidiary have been,
are and will continue to be in compliance with all applicable regulations and
requirements promulgated, or enforced by any Governmental Entity, Industry
Compliance Entity or Customer, except where the failure to establish and
implement such quality assurance and compliance programs would not, either
individually or in the aggregate, have a Material Adverse Effect on the Company.
(f) To the Company's knowledge, since May 27, 1999, neither
the Company nor any of its Subsidiaries, nor any officer, agent or employee of
the Company or any of its Subsidiaries acting for or on behalf of the Company or
any of its Subsidiaries, has paid or given, or caused to be offered, paid or
given, directly or indirectly, in connection with the business of the Company or
any of its Subsidiaries any bribe, kickback or other similar payment or
consideration to any Governmental Entity, Industry Compliance Entity, Customer
or supplier or any agent thereof.
(g) Since May 27, 1999, except as set forth in the Company
Disclosure Letter, to the Company's knowledge, the Company and each Subsidiary
has created, kept and submitted (as required) and continues to create, keep and
submit, all records, logs, reports and
19
files that are required by any Governmental Entity, Industry Compliance Entity
or Customer, or under any applicable law, regulation, rule, or accreditation
requirement to which the Company or such Subsidiary is subject, except where the
failure to create and keep such records, logs, reports and files would not,
either individually or in the aggregate, have a Material Adverse Effect on the
Company. All such records, logs, reports and files are maintained in accessible
form. In addition, except as set forth in the Company Disclosure Letter, the
Company and each Subsidiary has and continues to file or transmit on a timely
basis any and all necessary reports, filings or submissions of any kind required
by any applicable Governmental Entity, Industry Compliance Entity or Customer,
except where such failure to file or transmit on a timely basis or at all would
not, either individually or in the aggregate, have a Material Adverse Effect on
the Company.
(h) Except as set forth in the Company Disclosure Letter, from
the date of the Reference Balance Sheet to the date hereof, no employee or agent
of any of the Company or any Subsidiary, nor any Contract with a Customer, has
been terminated as a result of material misconduct, material noncompliance with
law, including failure to follow applicable laws, rules, regulations and
policies and procedures related to safety and quality.
(i) Except as set forth in the Company Disclosure Letter, to
the knowledge of the Company's Chief Executive Officer, no official of any
Governmental Entity or Industry Compliance Entity acting in his or her official
capacity, has, since May 27, 1999, made any statement, oral or written, to the
Company threatening to revoke or limit in any material manner any material
Permit of the Company or any of its Subsidiaries.
Section 5.13 EMPLOYEE PLANS. (a) The Company and each of its
Subsidiaries has complied in all material respects with and performed all
contractual obligations and all obligations under applicable federal, state and
local laws, rules and regulations (domestic and foreign) required to be
performed by it under or with respect to any of the Company Benefit Plans (as
hereinafter defined) or any related trust agreement or insurance contract. Each
Company Benefit Plan complies in all material respects with applicable law,
including, without limitation, ERISA and the Code. With respect to each Company
Benefit Plan intended to qualify under Section 401(a) of the Internal Revenue
Code of 1986, as amended (the "CODE"), the Company has received a determination
letter (which may be a determination letter or an opinion received by a sponsor
of a master and prototype standardized or paired plan) from the Internal Revenue
Service (or has submitted or is within the remedial amendment period for
submitting an application for a determination letter from the IRS) to the effect
that the Company Benefit Plan is qualified under Section 401 of the Code and any
trust maintained pursuant thereto is exempt from federal income taxation under
Section 501 of the Code and, to the Company's knowledge, nothing has occurred or
is expected to occur through the date of the Effective Time that caused or could
cause the loss of such qualification or exemption or the imposition of any
penalty or tax liability. No Company Benefit Plan is under audit or
investigation by the Internal Revenue Service, Department of Labor, or any other
governmental authority and no such completed audit, if any, has resulted in the
imposition of any tax or penalty. All contributions and other payments required
to be made by the Company or any of its Subsidiaries to any Company Benefit Plan
prior to the date hereof have been made, and all accruals required to be made
with respect to any Company Benefit Plan have been made. There is no claim,
dispute, grievance, charge, complaint, restraining or injunctive order,
litigation or proceeding pending, threatened or anticipated (other than
non-material claims or routine claims for benefits) against or relating to
20
any Company Benefit Plan or against the assets of any Company Benefit Plan. The
Company and each of its Subsidiaries has not communicated generally to employees
or specifically to any employee regarding any future increase of benefit levels
(or future creations of new benefits) with respect to any Company Benefit Plan
beyond those reflected in the Company Benefit Plans. The Company and each of its
Subsidiaries does not presently sponsor, maintain, contribute to, nor is the
Company required to contribute to, nor has the Company or any of its
Subsidiaries ever sponsored, maintained, contributed to, or been required to
contribute to, any employee pension benefit plan subject to Title IV or Section
302 of the Employee Retirement Income Security Act of 1974, as amended ("ERISA")
including, without limitation, any multiemployer plan within the meaning of
Section 3(37) or 4001(a)(3) of ERISA or Section 412 of the Code.
(b) Except as set forth in the Company Disclosure Letter, each
Company Benefit Plan can be terminated or otherwise discontinued without
liability to the Company or any of its Subsidiaries.
(c) Except as set forth in the Company Disclosure Letter, the
execution, delivery and performance of this Agreement and the transactions
contemplated hereby will not result in the imposition of any federal excise tax
with respect to any Company Benefit Plan. No non-exempt "prohibited
transaction," within the meaning of Section 4975 of the Code and Section 406 of
ERISA, has occurred or is expected to occur with respect to any Company Benefit
Plan (and the consummation of the transactions contemplated by this Agreement
will not constitute or directly or indirectly result in such a non-exempt
"PROHIBITED TRANSACTION").
(d) Except as set forth in the Company Disclosure Letter, no
payment or benefit which will or may be made by the Company or any of its
Subsidiaries with respect to any of their employees under any plan or agreement
in effect on the date hereof will be characterized as an "EXCESS PARACHUTE
PAYMENT" within the meaning of Section 280G(b)(1) of the Code or will fail to be
deductible for federal income tax purposes by virtue of Section 162(m) of the
Code.
(e) Except as set forth in the Company Disclosure Letter,
neither the Company nor any of its Subsidiaries maintains or contributes to (or
has maintained or contributed to) any Company Benefit Plan which provides, or
has a liability to provide, life insurance, medical, severance, or other
employee welfare benefit to any employee upon his retirement or termination of
employment, except as may be required by Section 4980B of the Code.
(f) Except as set forth in the Company Disclosure Letter, the
consummation of the transactions contemplated by this Agreement will not give
rise to any liability for severance pay, unemployment compensation, termination
pay, or withdrawal liability, or accelerate the time of payment or vesting or
increase the amount of compensation or benefits due to any employee, director,
or shareholder of the Company or any Subsidiary (whether current, former, or
retired) or their beneficiaries solely by reason of such transactions or by
reason of a termination following such transactions.
(g) Except as set forth in the Company Disclosure Letter,
neither the Company nor any Subsidiary has any unfunded liabilities pursuant to
any Company Benefit Plan
21
that is not intended to be qualified under Section 401(a) of the Code and is an
employee pension benefit plan within the meaning of Section 3(2) of ERISA, a
nonqualified deferred compensation plan or an excess benefit plan.
(h) Except as set forth in the Company Disclosure Letter,
neither the Company nor any of its Subsidiaries maintains or contributes to (or
has maintained or contributed to) any material employee benefit scheme or
arrangement mandated by a government other than the United States or a material
Company Benefit Plan that is not subject to United States law.
(i) Other than the Subsidiaries, there are no entities that
would be deemed or, within the past six years would have been deemed, a "single
employer" with the Company under Section 414(b), (c), (m), or (o) of the Code or
Section 4001 of ERISA.
(j) As used herein: "COMPANY BENEFIT PLAN" means any "EMPLOYEE
BENEFIT plan" within the meaning of Section 3(3) of ERISA and any other bonus,
incentive compensation, deferred compensation, pension, profit sharing,
retirement, leave of absence, layoff, vacation, day or dependent care, legal
services, cafeteria, life, health, accident, disability, workers' compensation
or other insurance, employment, payroll practice, consulting, severance,
separation or other employee benefit plan, practice, policy, agreement or
arrangement of any kind, established by the Company or any of its Subsidiaries
or to which the Company or any of its Subsidiaries contributes or has
contributed (including any such Company Benefit Plans not now maintained by the
Company or any of its Subsidiaries or to which the Company or any of its
Subsidiaries does not now contribute, but with respect to which the Company or
any of its Subsidiaries has or may have any liability). Copies of all Company
Benefit Plans (and, if applicable, related trust agreements) and all amendments
thereto and written interpretations thereof and the most recent Forms 5500
required to be filed with respect thereto and all other material documents
relating to any Company Benefit Plan have been furnished to Purchaser. The
Company Disclosure Letter sets forth (i) a true and correct list of each Company
Benefit Plan and (ii) each Company Benefit Plan with respect to which benefits
will be accelerated, vested, increased or paid as a result of the transactions
contemplated by this Agreement.
Section 5.14 EMPLOYMENT RELATIONS AND AGREEMENTS. (a) Except as set
forth in the Company Disclosure Letter, (i) to the Company's knowledge, the
Company and each of its Subsidiaries is, and at all times has been, in
compliance in all material respects with all federal, state or other applicable
laws respecting employment and employment practices, terms and conditions of
employment and wages and hours, and has not and is not engaged in any unfair
labor practice; (ii) no unfair labor practice complaint or charge against the
Company or any of its Subsidiaries is pending or to the Company's knowledge is
threatened before the National Labor Relations Board; (iii) there is no labor
strike, dispute, slowdown or stoppage actually pending or to the Company's
knowledge threatened against or involving the Company or any of its
Subsidiaries, and since May 27, 1999, neither the Company nor any of its
Subsidiaries has experienced any labor strike, dispute, slowdown or stoppage;
(iv) no representation question exists and to the Company's knowledge there has
been no effort to organize unorganized employees of the Company or any of its
Subsidiaries; (v) neither the Company nor any of its Subsidiaries is a party to
any collective bargaining agreement; and (vi) no collective bargaining agreement
is currently being negotiated by the Company or any of its Subsidiaries.
22
(b) Except as set forth in the Company Disclosure Letter,
neither the Company nor any of its Subsidiaries has any written, or to the
knowledge of the Company and its Subsidiaries, any binding oral employment
agreement which is not terminable by the Company and its Subsidiaries with
payment or penalty of less than $20,000. Copies of all employment agreements and
all amendments thereto were made available to Purchaser prior to the date hereof
and all such employment agreements are listed on the Company Disclosure Letter.
Section 5.15 CONTRACTS. (a) Neither the Company nor any of its
Subsidiaries is in default under or in violation of any provision of any
Contract (as hereinafter defined) except where such defaults or violations would
not, individually or in the aggregate, have a Material Adverse Effect on the
Company.
(b) Except as set forth in the Company Disclosure Letter,
neither the Company nor any of its Subsidiaries is a party to or bound by any
continuing:
(i) employment agreement or employment contract that has an
aggregate future liability in excess of $50,000 and is not terminable by
the Company or a Subsidiary by notice of not more than 60 days for a cost
of less than $50,000;
(ii) covenant of the Company or a Subsidiary not to compete;
(iii) agreement, contract or other arrangement with any
current officer or director of the Company or any Subsidiary (other than
employment agreements covered by clause (i) above);
(iv) lease, sublease or similar agreement involving annual
payments in excess of $100,000 with any Person (other than the Company or
a Subsidiary) under which the Company or a Subsidiary is a lessor or
sublessor of, or makes available for use to any Person (other than the
Company or a Subsidiary), (A) any Company Property (as hereinafter
defined) or (B) any portion of any premises otherwise occupied by the
Company or a Subsidiary;
(v) lease or similar agreement with any Person (other than the
Company or a Subsidiary) under which (A) the Company or a Subsidiary is
lessee of, or holds or uses, any machinery, equipment, vehicle or other
tangible personal property owned by any Person or (B) the Company or a
Subsidiary is a lessor or sublessor of, or makes available for use any
Person, any tangible personal property owned or leased by the Company or a
Subsidiary, in any such case which has an annual future liability or
receivable, as the case may be, in excess of $150,000 and is not
terminable by the Company or a Subsidiary by notice of not more than 60
days for a cost of less than $50,000;
(vi) continuing contract for the future purchase of materials,
supplies or equipment (other than purchase contracts and orders for
inventory in the ordinary course of business consistent with past
practice) in excess of $150,000 annually;
(vii) license, option or other agreement relating in whole or
in part to material Intellectual Property (including any license or other
agreement under which the
23
Company or a Subsidiary is licensee or licensor of any such material
Intellectual Property);
(viii) agreement, contract or other instrument under which the
Company or a Subsidiary has borrowed any money from, or issued any note,
bond, debenture or other evidence of indebtedness to, any Person (other
than the Company or a Subsidiary) or any other note, bond, debenture or
other evidence of indebtedness issued to any Person (other than the
Company or a Subsidiary);
(ix) agreement, contract or other instrument (including
so-called take-or-pay or keepwell agreements) under which (A) any Person
(including the Company or a Subsidiary) has directly or indirectly
guaranteed indebtedness, liabilities or obligations of the Company or a
Subsidiary or (B) the Company or a Subsidiary has directly or indirectly
guaranteed indebtedness, liabilities or obligations of any Person (in each
case other than endorsements for the purpose of collection in the ordinary
course of business);
(x) agreement, contract or other instrument under which the
Company or a Subsidiary has, directly or indirectly, made any advance,
loan, extension of credit or capital contribution in excess of $50,000 to,
or other investment in, any Person (other than the Company or a
Subsidiary);
(xi) mortgage, pledge, security agreement, deed of trust or
other instrument granting a material lien or other material encumbrance
upon any material Company Property;
(xii) agreement or instrument providing for indemnification of
any person with respect to liabilities relating to any current or former
business of the Company, a Subsidiary or any predecessor Person, excluding
any agreements or instruments providing for indemnification obligations
for which Life Sciences is solely responsible; or
(xiii) to the knowledge of the Company, any other material
agreement to which the Company or any Subsidiary is a party (except for
those agreements relating solely to the business of Life Sciences) not
covered by any of the categories specified in clauses (i) through (xii)
above.
(c) Except as set forth in the Company Disclosure Letter, all
agreements, contracts, leases, licenses, commitments or instruments of the
Company or any Subsidiary listed in the Company Disclosure Letter under this
Section 5.15 (collectively, the "CONTRACTS") are valid, binding and in full
force and effect and are enforceable by the Company or the relevant Subsidiary
in accordance with their terms, except where the failure of a Contract to be
valid, binding and in full force and effect and enforceable by the Company or
relevant Subsidiary would not have, individually or in the aggregate, a Material
Adverse Effect on the Company. Except as set forth in the Company Disclosure
Letter, the Company and the Subsidiaries have performed all material obligations
required to be performed by them to date under the Contracts and they are not
(with or without the lapse of time or the giving of notice, or both) in breach
or default in any material respect thereunder, except for such breach, default
or
24
failure of performance which would not have, individually or in the aggregate, a
Material Adverse Effect on the Company. Except as set forth in the Company
Disclosure Letter there are no change of control or similar provisions or any
obligations arising under any Contract which are created, accelerated or
triggered solely as a result of the execution, delivery or performance of this
Agreement or the consummation of the transactions contemplated hereby or
thereby.
(d) Except as set forth on the Company Disclosure letter,
there are no renegotiations of or, to the knowledge of the Company or its
Subsidiaries, attempts to renegotiate, or outstanding rights to renegotiate, any
material provisions of any Contracts with Customers, including without
limitation provisions relating to the term of such Contracts. Neither the
Company nor any of its Subsidiaries has received any written demand for such
renegotiation in respect of any such Contract with a Customer. Except as set
forth on the Company Disclosure Letter, no Customer has asserted that any
material adjustments are required to the terms of any such Contracts.
(e) Except as set forth in the Company Disclosure Letter, to
the Company's knowledge, neither the Company nor any of its Subsidiaries party
to a Contract has committed any act or omission which has given rise to, any
material product liability or material liability for breach of warranty on the
part of the Company or any of its Subsidiaries.
(f) As of the date hereof, neither the Company nor any of its
Subsidiaries is a party to any prime contract, subcontract, basic ordering
agreement, letter agreement, purchase order, delivery order, bid, change order
or other commitment relating to the business of the Company or any of its
Subsidiaries, between the Company or any of its Subsidiaries and the United
States Government, a U.S. state or municipal government or a department or
agency thereof.
Section 5.16 ENVIRONMENTAL LAWS AND REGULATIONS. (a) To the
knowledge of the Company, except as disclosed in the Company Disclosure Letter,
all of the current and past operations of the Company, including any operations
at or from any Company Properties, formerly owned, leased or operated real
properties ("FORMER COMPANY PROPERTIES"), materially comply and have at all
times during the Company's ownership, lease or operation thereof materially
complied with all applicable Environmental Laws. To the knowledge of the
Company, neither the Company, nor any other person or entity, has engaged in,
authorized, allowed or suffered any operations or activities upon any of the
Company Properties or Former Company Properties for the purpose of or in any way
involving the handling, manufacture, treatment, processing, storage, use,
generation, release, discharge, spilling, emission, dumping or disposal of any
Hazardous Substances at, on, under or from the Company Properties or Former
Company Properties, except in full compliance with all applicable Environmental
Laws.
(b) To the knowledge of the Company, none of the Company
Properties or Former Company Properties contains any Hazardous Substances in,
on, over, under or at it, in concentrations which violate any currently
applicable Environmental Laws or would be reasonably likely to result in the
imposition of an Environmental Liability on the "owner", lessee, manager, or
operator thereof under any applicable Environmental Laws, including any
liability or obligations for the investigation, corrective action, remediation
or monitoring of
25
Hazardous Substances in, on, over, under or at the Company Properties or Former
Company Properties.
(c) To the knowledge of the Company, none of the Company
Properties or Former Company Properties is listed or proposed for listing on the
National Priorities List pursuant to the Comprehensive Environmental Response,
Compensation and Liability Act ("CERCLA"), 42 U.S.C. 9601 et seq., or any
similar inventory of sites requiring investigation, monitoring or remediation
maintained by any state or locality. The Company has not received any written
notice from any Governmental Entity or third party of any actual or threatened
Environmental Liabilities.
(d) To the knowledge of the Company, there are no underground
storage tanks, asbestos or asbestos containing materials, polychlorinated
biphenyls, urea formaldehyde, or other Hazardous Substances in, on, over, under
or at any of the Company Properties.
(e) To the knowledge of the Company, there are no conditions
existing at any Company Properties or with respect to the business of the
Company or any Subsidiary, that require, or which with the giving of notice or
the passage of time or both will reasonably likely require remedial or
corrective action, removal, monitoring or closure pursuant to the Environmental
Laws.
(f) To the knowledge of the Company, the Company and its
Subsidiaries have all the permits, licenses, authorizations and approvals
necessary for the conduct of its business and for the operations on, in or at
the Company Properties (the "ENVIRONMENTAL PERMITS"), which are required under
applicable Environmental Laws. To the knowledge of the Company, the Company is
in material compliance with the terms and conditions of all such Environmental
Permits, and no reason exists why the Purchaser would not be capable of
continued operation of the business of the Company and its Subsidiaries in full
compliance with the Environmental Permits and the applicable Environmental Laws.
(g) The Company and its Subsidiaries have provided to
Purchaser all material environmental reports, assessments, audits, studies,
investigations, data, Environmental Permits and other written environmental
information in their custody, possession or control concerning the business of
the Company and its Subsidiaries, the Company Properties and the Former Company
Properties.
(h) Except as set forth in the Company Disclosure Letter, the
Company has not contractually, or to the knowledge of the Company by operation
of law or otherwise, assumed or succeeded to any Environmental Liabilities of
any predecessors or other person or entity.
For the purposes of this Agreement, the following terms shall have
the meanings set forth hereafter:
(i) "ENVIRONMENT" shall mean any surface or subsurface
physical medium or natural resource, including, air, land, soil, surface
waters, ground waters, stream and river sediments, biota and any indoor
area, surface or physical medium.
26
(ii) "ENVIRONMENTAL LAWS" shall mean any federal, state, local
or common law, rule, regulation, ordinance, code, order or judgment
(including any written judicial or administrative interpretations)
existing as of the date of this Agreement and relating to health, safety
or injury to, or the pollution or protection of the environment.
(iii) "ENVIRONMENTAL LIABILITIES" shall mean any claims,
judgments, damages (including punitive damages), losses, penalties, fines,
liabilities, encumbrances, liens, violations, costs and expenses
(including attorneys' and consultants' fees) relating to health, safety or
the environment of whatever kind or nature by, asserted by any party,
entity or Governmental Entity, (A) which are incurred as a result of (i)
the existence of Hazardous Substances in, on, under, at or emanating from
any of the Company Properties or Former Company Properties or in
connection with the operation of the business of the Company and its
Subsidiaries, (ii) the offsite transportation, treatment, storage or
disposal of Hazardous Substances generated by the business of the Company
and its Subsidiaries, (iii) the violation of or non-compliance with any
Environmental Laws, and (iv) exposure to any Hazardous Substances, noises,
odors, vibrations or other health or safety conditions or (B) which arise
under the Environmental Laws.
(iv) "HAZARDOUS SUBSTANCES" shall mean petroleum, petroleum
products, petroleum-derived substances, radioactive materials, hazardous
wastes, polychlorinated biphenyls, lead-based paint, radon, urea
formaldehyde, asbestos or any materials containing asbestos, pesticides,
and any chemicals, materials or substances regulated under any
Environmental Law, or defined as or included in the definition of
"hazardous substances," "hazardous wastes", "extremely hazardous
substances," "hazardous materials," "hazardous constituents," "toxic
substances," "pollutants," "contaminants" or any similar denomination
intended to classify or regulate chemicals, materials or substances by
reason of toxicity, carcinogenicity, ignitability, corrosivity or
reactivity, under any Environmental Law.
Section 5.17 REAL PROPERTY AND LEASES. (a) The Company Disclosure
Letter sets forth a complete and accurate list and the address of all real
property and interests in real property owned in fee by the Company and the
Subsidiaries (individually, an "OWNED PROPERTY"). The Company Disclosure Letter
sets forth a complete list of (i) all real property and interests in real
property leased or sub-leased by the Company and the Subsidiaries (individually,
a "LEASED PROPERTY") and (ii) each plasma collection center operated by the
Company or its Subsidiaries as of the date hereof. To the knowledge of the
Company, the Company or a Subsidiary has (i) good and insurable fee title to all
Owned Property and (ii) good and valid title to the leasehold estates in all
Leased Property (an Owned Property or Leased Property being sometimes referred
to herein, individually, as a "COMPANY PROPERTY" and, collectively, as "COMPANY
PROPERTIES"), in each case free and clear of all mortgages, liens, security
interests, encumbrances, leases, assignments, subleases, easements, covenants,
rights-of-way and other similar restrictions of any nature whatsoever, except
(A) such as are set forth in the Company Disclosure Letter, (B) exceptions
specified in the Title Policies (as hereinafter defined), (C) Permitted Liens
(as hereinafter defined), (D) financing statements, easements, covenants,
rights-of-way and other similar restrictions of record and (E) (I) zoning,
building and other similar restrictions, (II) mortgages, liens, security
interests, encumbrances, easements, covenants, rights-of-way and other similar
restrictions that have been placed by any developer, landlord or
27
other third party on property over which the Company or any Subsidiary has
easement rights or on any Leased Property and subordination or similar
agreements relating thereto, and (III) unrecorded easements, covenants,
rights-of-way and other similar restrictions, none of which items set forth in
clauses (I), (II) and (III), individually or in the aggregate, materially impair
the continued use and operation of the property to which they related in the
business of the Company and the Subsidiaries, taken as a whole, as presently
conducted. The rental set forth in each lease or sublease of the Leased Property
is the actual rental being paid, and there are no separate agreements or
understandings with respect to the same. Except as set forth on the Company
Disclosure Letter, to the knowledge of the Company and its Subsidiaries, the
current use by the Company and the Subsidiaries of the offices and other
facilities located on Company Property does not violate any local zoning or
similar land use or government regulations in any material respect. As used in
this Agreement, the term "LIENS" shall mean all liens, mortgages, deeds of
trust, deeds to secure debt, security interests, pledges, claims, charges,
easements and other encumbrances of any nature whatsoever. As used in this
Agreement, the term "PERMITTED LIENS" shall mean (i) Liens for taxes or other
assessments or charges of Governmental Entities that are not yet delinquent or
that are being contested in good faith by appropriate proceedings, in each case,
with respect to which adequate reserves are being maintained by the Company or
its Subsidiaries to the extent required by GAAP, (ii) statutory Liens of
landlords, carriers, warehousemen, mechanics, materialmen and other Liens
imposed by law and created in the ordinary course of business for amounts not
yet overdue or which are being contested in good faith by appropriate
proceedings, in each case, with respect to which adequate reserves or other
appropriate provisions are being maintained by the Company or its Subsidiaries
to the extent required by GAAP, (iii) easements, rights-of-way, covenants and
restrictions which do not (x) interfere materially with the ordinary conduct of
any Company Property or the business of the Company and its Subsidiaries as a
whole or (y) detract materially from the value or usefulness of the Company
Properties to which they apply, and (iv) the other Liens, if any, specified in
the Company Disclosure Letter.
(b) The Company Disclosure Letter sets forth a complete and
accurate list of all material commitments, letters of intent or similar written
understandings made or entered into by the Company or any of its Subsidiaries as
of the date hereof (x) to sell, mortgage, pledge or hypothecate any Owned
Properties, which, individually or in the aggregate, are material, or to
otherwise enter into a material transaction in respect of the ownership or
financing of any Company Property or (y) to purchase or to acquire an option,
right of first refusal or similar right in respect of any real property, which,
individually or in the aggregate, are material, which, in any such case, has not
yet been reduced to a written lease or contract, and sets forth with respect to
each such commitment, letter of intent or other understanding the principal
terms thereof. The Company has delivered to Purchaser a true and complete copy
of each such commitment, letter of intent or other understanding. The Company
Disclosure Letter also sets forth a complete and accurate list of all agreements
to purchase real property to which the Company or any Subsidiary is a party.
(c) To the knowledge of the Company, except as set forth in
the Company Disclosure Letter, none of the Company Properties is subject to any
outstanding purchase options nor has the Company or any of its Subsidiaries
entered into any outstanding contracts with others for the sale, mortgage,
pledge, hypothecation, assignment, sublease, lease or other transfer of all or
any part of any Company Property, and no person has any right or
28
option to acquire, or right of first refusal with respect to, the Company's or
any of its Subsidiaries' interest in any Company Property or any part thereof.
Except as set forth in the Company Disclosure Letter, none of the Company or any
of its Subsidiaries has any outstanding options or rights of first refusal or
has entered into any outstanding contracts with others for the purchase of any
real property.
(d) The Company Disclosure Letter contains a complete and
accurate description of any material noncompliance in respect of any Company
Property, with any law, ordinance, code, health and safety regulation or
insurance requirement. Except as set forth in the Company Disclosure Letter, to
the knowledge of the Company, there are no outstanding or threatened
requirements by any insurance company which has issued an insurance policy
covering any Company Property, or by any board of fire underwriters or other
body exercising similar functions, requiring any repairs or alterations to be
made to any Company Property.
Section 5.18 CUSTOMERS. Listed in the Company Disclosure Letter are
the names and addresses of all the customers of the Company or any of its
Subsidiaries ("CUSTOMERS") that ordered, during each of the following indicated
periods, Company Products and Services with an aggregate value in excess of (i)
$500,000 during the Company's fiscal year ended February 29, 2000 and (ii)
$500,000 during the nine months ended November 30, 2000 and the approximate
amount during such period for which each such Customer was invoiced. Except as
disclosed in the Company Disclosure Letter, as of the date hereof neither the
Company nor any Subsidiary has received any written notice that any of its
Customers has ceased, or will cease, to use the Company Products and Services,
or has substantially reduced, or will substantially reduce, the use of the
Company Products and Services during the six-month period immediately following
the date hereof. The Company Disclosure Letter sets forth a true and correct
list of those blood plasma collection centers the collection of plasma from
which is covered by existing agreements with customers other than Purchaser and
the periods covered thereby. Each Customer to which the output of such centers
is committed does not have the unilateral right to extend the term for which the
Company is obligated to deliver source plasma under the agreements pertaining
thereto. The Company does not have any obligation to perform serology testing
for any Customer other than Purchaser.
Section 5.19 SUPPLIERS. Listed in the Company Disclosure Letter are
the names and addresses of all the suppliers of the Company or of any of its
Subsidiaries that sold goods or merchandise to the Company or such Subsidiary
with an aggregate value in excess of (i) $300,000 during the fiscal year ended
February 29, 2000 and (ii) $300,000 during the nine months ended November 30,
2000 and the approximate amount during such period for which the Company or such
Subsidiary was invoiced by each such supplier. Except as disclosed in the
Company Disclosure Letter, as of the date hereof neither the Company nor any of
its Subsidiaries has received any written notice that any such supplier will not
sell raw materials, supplies, merchandise and other goods to the Company or its
Subsidiaries during the six-month period immediately following the date hereof
on terms and conditions substantially similar to those currently in effect,
subject only to general and customary price increases.
Section 5.20 INTELLECTUAL PROPERTY. The Company and its Subsidiaries
have rights to use, whether through ownership, licensing or otherwise, all
patents, trademarks, service marks, tradenames, copyrights, trade secrets,
licenses, information, proprietary rights and
29
processes that are material to the conduct of the business of the Company and
its Subsidiaries (collectively, the "INTELLECTUAL PROPERTY RIGHTS"). Except as
set forth in the Company Disclosure Letter, to the Company's knowledge, there
are no infringements by any other party of any of the Intellectual Property
Rights.
Section 5.21 INSURANCE. The Company Disclosure Letter contains a
true and correct list in all material respects of all insurance policies of the
Company and its Subsidiaries. The Company Disclosure Letter sets forth a true
and correct list of any claims in excess of $25,000 made by the Company or its
Subsidiaries since May 27, 1999 under any insurance policies maintained by the
Company or a Subsidiary during such period.
Section 5.22 TAKEOVER STATUTES. Assuming the accuracy of the
representation of Purchaser in Section 4.5, the Board of Directors of the
Company has approved this Agreement and the Voting Agreements and the
transactions contemplated hereby and thereby for purposes of Section 203 of the
DGCL.
Section 5.23 TAXES. Except as set forth in the Company Disclosure
Letter, (i) the Company and each of its Subsidiaries has filed all material Tax
Returns (as hereinafter defined) required to have been filed on or before the
date hereof, except where the failure to file any such Tax Return would not have
a Material Adverse Effect on the Company, which returns are true and complete in
all material respects, except where any failure with respect thereto would not
have a Material Adverse Effect on the Company; (ii) the Company and each of its
Subsidiaries has duly paid or accrued as liabilities on its books all material
Taxes (as hereinafter defined) (including material estimated Taxes and any
interest or penalties) which are due and payable on or before the date hereof
(whether or not shown on any such Tax Return), except where GAAP does not
require an accrual or where such failure to pay or accrue would not have a
Material Adverse Effect on the Company, and the Company and each of its
Subsidiaries has withheld or collected and paid pursuant to applicable law all
material Taxes they are required to withhold, collect and pay, except where any
failure to withhold, collect or pay would not have a Material Adverse Effect on
the Company; (iii) neither the Company nor any of its Subsidiaries has waived
any statute of limitations in respect of material Taxes of the Company or any of
its Subsidiaries; (iv) neither the Company nor any of its Subsidiaries has
received notice of any audit, investigation, examination or other administrative
or judicial proceeding concerning Taxes currently being conducted by the
relevant taxing authority with respect to the Company or any Subsidiary; (v) no
material issues that have been raised in writing by the relevant taxing
authority in connection with the examination of the Tax Returns referred to in
clause (i) are currently pending, except where any such issue would not have a
Material Adverse Effect on the Company; (vi) all material Tax deficiencies
asserted or Tax assessments made in writing as a result of any examination of
the Tax Returns referred to in clause (i) by a taxing authority have been
accrued on the books of the Company or its Subsidiaries or paid in full; (vii)
there are no material tax liens on any assets of the Company or any Subsidiary
other than Permitted Liens; (viii) none of the Company or any of the
Subsidiaries has filed a consent under Section 341(f) of the Code concerning
collapsible corporations; and (ix) as of the date hereof, giving effect to the
Spin-Off, no interest in the Company constitutes a "United States real property
interest" within the meaning of Section 897(c) of the Code. For purposes of this
Agreement (a) "TAX" (and, with correlative meaning, "TAXES" and "Taxable") means
any federal, state, local or foreign income, gross receipts, property, sales,
use, license, excise, franchise, employment, payroll, premium,
30
withholding, alternative or added minimum, ad valorem, transfer or excise tax,
or any other tax, custom, duty, governmental fee or other like assessment or
charge of any kind whatsoever, together with any interest or penalty, imposed by
any governmental authority, and (b) "TAX RETURN" means any return, report or
similar statement required to be filed with respect to any Tax (including any
attached schedules), including, without limitation, any information return,
claim for refund, amended return or declaration of estimated Tax.
Section 5.24 ACCOUNTS; LOCKBOXES; SAFE DEPOSIT BOXES. The Company
Disclosure Letter contains a true and complete list of: (i) the names of each
bank, savings and loan association, securities or commodities broker or other
financial institution in which the Company or any of its Subsidiaries has an
account, including cash contribution accounts, and the names of all persons
authorized to draw thereon or have access thereto; and (ii) the location of all
lockboxes and safe deposit boxes of the Company or any of its Subsidiaries.
Section 5.25 BROKERS. (a) (a) No broker, investment banker or other
person, other than VSI Advisors, L.L.C. ("VSI ADVISORS") and CIBC World Markets
Corp. ("CIBC WORLD MARKETS"), the fees and expenses of which will be paid by the
Company, is entitled to any broker's, finder's or other similar fee or
commission in connection with the transactions contemplated by this Agreement
based upon arrangements made by or on behalf of the Company. A copy of the
engagement letter between VSI Advisors and the Company setting forth the fees
and expenses to be paid by the Company in connection with the transactions
contemplated by this Agreement has been provided to Purchaser.
(b) From February 12, 2001 through the date hereof, neither
the Company or its Subsidiaries nor, to the knowledge of the Company, any of its
or any of its Subsidiaries' officers, directors, employees, agents and
representatives (including, without limitation, any investment banker, attorney
or accountant retained by it or any of its Subsidiaries) has initiated,
solicited or encouraged, directly or indirectly, any inquiries or the making or
implementation of any Alternative Proposal (as hereinafter defined).
Section 5.26 CERTAIN INTERESTS. The Company Disclosure Letter
contains a complete and correct list of all agreements, contracts, transfers of
assets or liabilities or other commitments or transactions, to or by which the
Company or any of its Subsidiaries, on the one hand, and the directors or
executive officers of the Company or any of its Subsidiaries, on the other hand,
are or have been a party, and that (i) are currently pending or in effect or
(ii) involve continuing obligations that, individually or in the aggregate, have
been, are or will be material to the Company and its Subsidiaries taken as a
whole. Except as disclosed in the Company Disclosure Letter, to the Company's
knowledge, neither the Company nor any Subsidiary, nor any officer or director
of either the Company or any Subsidiary or any Immediate Family Member of such
officer or director, has any material financial interest in any competitor,
supplier or Customer of either the Company or any Subsidiary.
Section 5.27 FAIRNESS OPINION. The Board of Directors of the Company
has received from CIBC World Markets an opinion, dated the date of this
Agreement, to the effect that, as of such date, the Merger Consideration is
fair, from a financial point of view, to the holders of Shares.
31
Section 5.28 VOLUME OF PLASMA COLLECTED. The Company Disclosure
Letter sets forth the true and correct amount of total liters of blood plasma
collected by the Company for the Company's fiscal year ended February 28, 2001
(the "Annual Plasma Volume"). For the three month period consisting of March,
April and May, 2001, the volume of total liters of blood plasma collected by the
Company exceeded an annualized rate of 770,000 liters.
Section 5.29 DISCLOSURES. To the knowledge of the Company, this
Agreement and the Company Disclosure Letter, taken as a whole, do not contain
any untrue statement of material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements contained
herein, in light of the circumstances under which they were made, not
misleading.
Section 5.30 LIFE SCIENCES. Since January 1, 2001 through the date
hereof, there has been no material change in intercompany pricing between Life
Sciences and the Company. There are no material assets owned by Life Sciences
that are used in the source plasma collection business of the Company and its
Subsidiaries (other than Life Sciences).
ARTICLE VI
REPRESENTATIONS AND WARRANTIES REGARDING SUB
Purchaser and Sub jointly and severally represent and warrant to the
Company as follows:
Section 6.1 ORGANIZATION AND STANDING. Sub is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware. Sub is wholly owned by Purchaser and was organized solely for the
purpose of acquiring the Company and engaging in the transactions contemplated
by this Agreement and has not engaged in any business since it was incorporated
which is not in connection with the acquisition of the Company and this
Agreement.
Section 6.2 AUTHORITY; NON-CONTRAVENTION. The Board of Directors of
Sub has declared this Agreement advisable, fair to and in the best interest of
Sub and its stockholders. Sub has the requisite power and authority to enter
into this Agreement and to consummate the transactions contemplated hereby. The
execution and delivery of this Agreement, the performance by Sub of its
obligations hereunder and the consummation of the transactions contemplated
hereby have been duly authorized by its Board of Directors and Purchaser as its
sole stockholder and, except for the filing of the Certificate of Merger, no
other corporate proceedings on the part of Sub are necessary to authorize this
Agreement and the transactions contemplated hereby. This Agreement has been duly
and validly executed and delivered by Sub and (assuming the due authorization,
execution and delivery hereof by the Company) constitutes a valid and binding
obligation of Sub enforceable against Sub in accordance with its terms, except
as the enforceability thereof may be limited by creditors' rights generally or
by general principles of equity. The execution and delivery of this Agreement
does not, and the consummation of the transactions contemplated hereby and
compliance with the provisions hereof will not, conflict with, or result in any
violation of, or default (with or without notice or
32
lapse of time, or both) under, or give rise to a right of termination,
cancellation or acceleration of any obligation or to the loss of a material
benefit under, or result in the creation of any lien, security interest, charge
or encumbrance upon any of the properties or assets of Sub under, any provision
of (i) the certificate of incorporation or by-laws of Sub, (ii) any loan or
credit agreement, note, bond, mortgage, indenture, lease or other agreement,
instrument, permit, concession, franchise or license applicable to Sub or (iii)
any judgment, order, decree, statute, law, ordinance, rule or regulation
applicable to Sub or any of its properties or assets, other than, in the case of
clause (ii) or (iii), any such conflicts, violations, defaults, rights, liens,
security interests, charges or encumbrances that, individually or in the
aggregate, would not have a Material Adverse Effect on Sub, materially impair
the ability of Sub to perform its obligations hereunder or prevent the
consummation of any of the transactions contemplated hereby.
ARTICLE VII
COVENANTS RELATING TO CONDUCT OF BUSINESS
Section 7.1 CONDUCT OF BUSINESS BY THE COMPANY PENDING THE MERGER.
Except (i) for actions taken by Life Sciences with respect to its business that
do not, individually or in the aggregate, have a Material Adverse Effect on the
Company (after giving effect to the Spin-Off), (ii) as otherwise expressly
contemplated by this Agreement or (iii) as set forth in the Company Disclosure
Letter, during the period from the date of this Agreement through the Effective
Time, the Company shall, and shall cause each of its Subsidiaries to, in all
material respects carry on its business in, and not enter into any material
transaction other than in accordance with, the regular and ordinary course and,
to the extent consistent therewith, use commercially reasonable efforts to
preserve intact its current business organization, keep available the services
of its current officers and key employees and preserve its relationships with
its material customers, suppliers and others having material business dealings
with it. Without limiting the generality of the foregoing, and except as
otherwise expressly contemplated by this Agreement, the Spin-Off Agreements or
as set forth in the Company Disclosure Letter, the Company shall not, and shall
cause each of its Subsidiaries not to:
(a) other than in connection with (i) the conversion of
Preferred Stock into Common Stock or the redemption thereof in accordance with
their current terms, (ii) the exercise of options and warrants outstanding prior
to the date hereof in accordance with their current terms, (iii) the payment of
dividends on the Preferred Stock in accordance with their current terms and (iv)
the Spin-Off, (x) declare, set aside or pay any dividends on, or make any other
actual, constructive or deemed distributions in respect of, any of its capital
stock, or otherwise make any payments to its stockholders in their capacity as
such, other than dividends declared prior to the date of this Agreement, (y)
split, combine or reclassify any of its capital stock or issue or authorize the
issuance of any other securities in respect of, in lieu of or in substitution
for shares of its capital stock or (z) purchase, redeem or otherwise acquire any
shares of capital stock of the Company or any of its Subsidiaries or any other
securities thereof or any rights, warrants or options to acquire any such shares
or other securities;
(b) issue, deliver, sell, pledge, dispose of or otherwise
encumber any shares of its capital stock, any other voting securities or equity
equivalent or any securities
33
convertible into, or any rights, warrants or options to acquire, any such
shares, voting securities or convertible securities or equity equivalent (other
than as specified in clauses (i) through (iv) of paragraph (a) above);
(c) amend its certificate of incorporation or by-laws;
(d) acquire or agree to acquire by merging or consolidating
with, or by purchasing a substantial portion of the assets of or equity in, or
by any other manner, any business or any corporation, partnership, association
or other business organization or division thereof or otherwise acquire or agree
to acquire any assets that in the aggregate have a value in excess of 1% of the
Company's assets (except for the purchase of supplies and raw materials in the
ordinary course of the Company's business), provided that (i) Purchaser shall
not unreasonably withhold its consent to the Company's acquisition of additional
plasma collection centers with an aggregate purchase price not exceeding
$1,000,000 and (ii) Purchaser's consent shall not be required for the
acquisition by the Company of the plasma collection center described in that
certain bid letter, dated May 9, 2001, prepared by the Company, a copy of which
has been previously provided to Purchaser;
(e) sell, lease or otherwise dispose of, or agree to sell,
lease or otherwise dispose of, any of its assets that in the aggregate have a
value in excess of 1% of the Company's assets (except for sales of assets,
including the sale of inventory, in the ordinary course of the Company's
business);
(f) amend or otherwise modify in any material respect, or
terminate, any material Contract, or enter into any joint venture, material
lease or material management agreement or other material agreement of the
Company or any of its Subsidiaries, except where any such action would not,
individually or in the aggregate, have a Material Adverse Effect on the Company,
provided that the Company may amend its contract with Centeon Bio-Services, Inc.
without the consent of Purchaser so long as such amendment does not (i) increase
the volume of plasma to be provided by the Company under such agreement, (ii)
extend the term of such agreement, or (iii) modify the pricing terms of such
agreement in a manner materially adverse to the Company.
(g) except for borrowings in the ordinary course under its
credit facility and incurrence of trade payables in the ordinary course of the
Company's business, incur any additional indebtedness (including for this
purpose any indebtedness evidenced by notes, debentures, bonds, leases or other
similar instruments, or secured by any lien on any property, conditional sale
obligations, obligations under any title retention agreement and obligations
under letters of credit or similar credit transaction) in a single transaction
or a group of related transactions, enter into a guaranty, or engage in any
other financing arrangements having a value in excess of 1% of the Company's
assets, or make any loans, advances or capital contributions to, or investments
in, any other Person; provided, however, that Purchaser's consent shall not be
required for borrowings by the Company or any of its Subsidiaries in connection
with asset acquisitions consented to by Purchaser or for which consent is not
required pursuant to Section 7.1(d);
34
(h) alter through merger, liquidation, reorganization,
restructuring or similar action its corporate structure or ownership;
(i) except as may be required as a result of a change in law
or in generally accepted accounting principles, change any of the accounting
principles or practices used by it;
(j) except as required in accordance with generally accepted
accounting principles, revalue any of its assets, including, without limitation,
writing down the value of its inventory or writing off notes or accounts
receivable, other than in the ordinary course of business;
(k) make any tax election, change any annual tax accounting
period, amend any tax return, settle or compromise any income tax liability,
enter into any closing agreement, settle any tax claim or assessment, surrender
any right to claim a tax refund or fail to make the payments or consent to any
extension or waiver of the limitations period applicable to any tax claim or
assessment, except where any such action would not have a Material Adverse
Effect on the Company;
(l) settle or compromise any pending suit, action or claim for
an amount exceeding $100,000, provided that (i) Purchaser's consent is not
required for any settlement in respect of the current arbitration involving Life
Sciences up to the amount reserved in the Company Financial Statements as of the
date hereof, and (ii) Purchaser's consent shall not be required where the
Company or any of its Subsidiaries is the plaintiff party and is paying less
than $100,000 to settle or compromise such pending suit, action or claim;
(m) except for the payment of bonuses up to an aggregate
amount of $500,000 to directors, officers and/or other employees based on fiscal
year 2001 performance, materially increase in any manner the compensation or
fringe benefits of any of its directors, officers and other key employees or pay
any material benefit not required by any existing plan or agreement to any such
employees, or become a party to, amend or commit itself to any pension,
retirement, profit-sharing or welfare benefit plan or agreement or employment
agreement or any other type of Company Benefit Plan with or for the benefit of
any employee, other than increases in the compensation of employees who are not
officers or directors of the Company or any of its Subsidiaries made in the
ordinary course of business consistent with past practice, or, except to the
extent required by law, voluntarily accelerate the vesting of any compensation
or benefit;
(n) waive, amend or allow to lapse any material term or
material condition of any material confidentiality or "standstill" agreement to
which the Company is a party;
(o) change the Company's dividend policy;
(p) enter into any transaction with a director or executive
officer of the Company or any of its Subsidiaries or any Immediate Family Member
of any such director or executive officer other than in the ordinary course of
business consistent with past practices;
35
(q) enter into any business other than the ownership,
management, operation and development of the Company Products and Services and
business related thereto;
(r) pursuant to or within the meaning of any bankruptcy law,
(i) commence a voluntary case, (ii) consent to the entry of an order for relief
against it in an involuntary case, (iii) consent to the appointment of a
custodian of it or for all or substantially all of its property or (iv) make a
general assignment for the benefit of its creditors;
(s) purchase or lease or enter into a binding agreement to
purchase or lease any material real property; provided, however, that
Purchaser's consent shall not be required (i) for leases entered into by the
Company or any of its Subsidiaries in connection with asset acquisitions
consented to by Purchaser or for which consent is not required pursuant to
Section 7.1(d), (ii) to the exercise by the Company or any of its Subsidiaries
of renewal or extension options on existing leases and (iii) to the
renegotiation by the Company or any of its Subsidiaries of existing leases to
extend the term of any such leases; provided that in the case of either clause
(ii) or (iii) of this Section 7.1(s), such exercise of renewal or extension
options on existing leases or renegotiation of existing leases shall be effected
on the basis of market rates applicable to the geographic areas in respect of
such leases;
(t) enter into any employment agreement with any officer or
key employee; or
(u) take, or agree in writing or otherwise to take, any of the
foregoing actions.
Section 7.2 CONSULTATION WITH PURCHASER. During the period from the
date hereof through the Effective Time, as reasonably requested by Purchaser,
senior management of the Company shall consult with Purchaser concerning
significant matters affecting the business of the Company.
Section 7.3 CONDUCT OF BUSINESS OF SUB PENDING THE MERGER. During
the period from the date of this Agreement through the Effective Time, Sub shall
not engage in any activities of any nature except as provided in or contemplated
by this Agreement.
ARTICLE VIII
ADDITIONAL AGREEMENTS
Section 8.1 PROXY STATEMENT. The Company shall use commercially
reasonable efforts to promptly prepare and file with the SEC the proxy statement
of the Company with respect to the Special Meeting (the "PROXY STATEMENT") and
obtain and furnish the information required to be included by it in the Proxy
Statement and, after consultation with Purchaser, respond promptly to any
comments made by the SEC with respect to the Proxy Statement and any preliminary
version thereof. The Company shall, as promptly as practicable, provide to
Purchaser copies of any written comments received from the SEC with respect to
the Proxy Statement and advise Purchaser of any oral comments with respect to
the Proxy Statement received from the SEC. Purchaser agrees that none of the
information supplied or to be supplied
36
by Purchaser for inclusion or incorporation by reference in the Proxy Statement
and each amendment or supplement thereto, at the time of mailing thereof and at
the time of the Special Meeting, will contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they
were made, not misleading. The Company agrees that none of the information
supplied or to be supplied by the Company for inclusion or incorporation by
reference in the Proxy Statement and each amendment or supplement thereto, at
the time of mailing thereof and at the time of the Special Meeting, will contain
an untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading. For purposes of
the foregoing, it is understood and agreed that information concerning or
related to Purchaser or Sub will be deemed to have been supplied by Purchaser
and information concerning or related to the Company shall be deemed to have
been supplied by the Company.
Section 8.2 INDEMNIFICATION. (a) In the event of any threatened or
actual claim, action, suit, demand, proceeding or investigation, whether civil,
criminal or administrative, including, without limitation, any such claim,
action, suit, demand, proceeding or investigation in which any person who is
now, or has been at any time prior to the date hereof, or who becomes prior to
the Effective Time, a director, officer, employee, fiduciary or agent of the
Company or any Subsidiary of the Company (the "INDEMNIFIED PARTIES") is, or is
threatened to be, made a party based in whole or in part on, or arising in whole
or in part out of, or pertaining to (i) the fact that he is or was a director,
officer, employee, fiduciary or agent of the Company or any Subsidiary of the
Company, or is or was serving at the request of the Company or any Subsidiary of
the Company as a director, officer, employee, fiduciary or agent of another
corporation, partnership, joint venture, trust or other enterprise or (ii) the
negotiation, execution or performance of this Agreement or any of the
transactions contemplated hereby, whether in any case asserted or arising before
or after the Effective Time, the parties hereto agree to cooperate and use their
commercially reasonable efforts to defend against and respond thereto. It is
understood and agreed that the Company shall indemnify and hold harmless, and
after the Effective Time, Purchaser shall cause the Surviving Corporation to,
and the Surviving Corporation shall, indemnify and hold harmless, as and to the
full extent permitted by applicable Law, each Indemnified Party against any
losses, claims, damages, liabilities, costs, expenses (including reasonable
attorneys' fees and expenses), judgments, fines and amounts paid in settlement
in connection with any such threatened or actual claim, action, suit, demand,
proceeding or investigation, and in the event of any such threatened or actual
claim, action, suit, demand, proceeding or investigation (whether asserted or
arising before or after the Effective Time), (A) the Company, and after the
Effective Time, Purchaser shall cause the Surviving Corporation to, and the
Surviving Corporation shall, promptly pay expenses in advance of the final
disposition of any claim, suit, proceeding or investigation to each Indemnified
Party to the full extent permitted by law, subject to the provision by such
Indemnified Party of an undertaking to reimburse the amounts so advanced in the
event of a final non-appealable determination by a court of competent
jurisdiction that such Indemnified Party is not entitled to such amounts, (B)
the Indemnified Parties may retain one counsel satisfactory to them (except in
case of a conflict of interest among two or more Indemnified Parties, in which
case more than one counsel may be retained), and the Company, and after the
Effective Time, Purchaser shall cause the Surviving Corporation to, and the
Surviving Corporation shall, pay all reasonable fees and expenses of such
counsel for the Indemnified Parties within 30 days after statements
37
therefore are received and (C) the Company and the Surviving Corporation will,
and Purchaser will cause the Surviving Corporation to, use their commercially
reasonable efforts to assist in the defense of any such matter; provided that
neither the Company nor the Surviving Corporation shall be liable for any
settlement effected without its prior written consent (which consent shall not
be unreasonably withheld); and provided further, that the Surviving Corporation
shall have no obligation hereunder to any Indemnified Party when and if, but
only to the extent that, a court of competent jurisdiction shall ultimately
determine, and such determination shall have become final and non-appealable,
that indemnification of such Indemnified Party in the manner contemplated hereby
is prohibited by applicable law. Any Indemnified Party wishing to claim
indemnification under this Section 8.2, upon learning of any such claim, action,
suit, demand, proceeding or investigation, shall notify the Company and, after
the Effective Time, the Surviving Corporation, thereof; provided that the
failure to so notify shall not affect the obligations of the Company and the
Surviving Corporation except to the extent such failure to notify materially
prejudices such party. Purchaser hereby unconditionally and irrevocably
guarantees for the benefit of the Indemnified Parties the obligations of the
Surviving Corporation under the foregoing indemnification arrangements,
including any such existing indemnification agreements to which the Company is a
party.
(b) Purchaser and Company agree that all rights to
indemnification existing in favor of, and all exculpations and limitations of
the personal liability of, the directors, officers, employees and agents of the
Company and the Subsidiaries of the Company in the Certificate of Incorporation
and By-Laws of the Company as in effect as of the date hereof with respect to
matters occurring at or prior to the Effective time, including the Merger, shall
continue in full force and effect for a period of not less than six years from
the Effective Time; provided, however, that all rights to indemnification in
respect of any claims (each, a "CLAIM") asserted or made within such period
shall continue until the disposition of such Claim. For a period of six years
after the Effective Time, the Surviving Corporation shall, and Purchaser shall
cause the Surviving Corporation to, cause to be maintained in effect the
existing directors' and officers' liability insurance and fiduciary insurance
policies with an amount of coverage not less than one hundred percent (100%) of
the amount of existing coverage and with at least the same scope of the existing
coverage, or policies that are no less favorable to the Indemnified Parties, and
with an amount of coverage not less than one hundred percent (100%) of the
amount of existing coverage, than the policies which are currently maintained by
the Company, with respect to claims arising from facts or events which occurred
at or before the Effective Time, so long as such policies are available for an
annual premium which is no more than two hundred percent (200%) of the current
annual premium for the existing policies; provided, that if such policies are
not available for an annual premium of no more than two hundred percent (200%)
of the current annual premium, then policies in an amount and scope as great as
can be obtained for an annual premium of two hundred percent (200%) of the
current annual premium shall be obtained.
(c) This Section 8.2 is intended for the irrevocable benefit
of, and to grant third party rights to, the Indemnified Parties and shall be
binding on all successors and assigns of Purchaser, the Company and the
Surviving Corporation. Each of the Indemnified Parties shall be entitled to
enforce the covenants contained in this Section 8.2.
(d) In the event that the Surviving Corporation or any of its
successors or assigns (i) consolidates with or merges into any other person or
entity and shall not be the
38
continuing or surviving entity of such consolidation or merger or (ii) transfers
or conveys a majority of its properties and assets to any person or entity,
then, and in each such case, proper provision shall be made so that the
successors, assigns and transferees of the Surviving Corporation, as the case
may be, assume the obligations set forth in this Section 8.2.
(e) To the extent permitted by law, all rights of
indemnification and advancement of expenses for the benefit of any Indemnified
Party shall be mandatory rather than permissive.
Section 8.3 ADDITIONAL AGREEMENTS. (a) Subject to the terms and
conditions herein provided, each of the parties hereto agrees to use all
commercially reasonable efforts to take, or cause to be taken, all actions and
to do, or cause to be done, all things necessary, proper or advisable under
applicable laws and regulations to consummate and make effective the
transactions contemplated by this Agreement, including using all commercially
reasonable efforts to obtain all necessary waivers, consents and approvals, to
effect all necessary registrations and filings and to lift any injunction to the
Merger (and, in such case, to proceed with the Merger as expeditiously as
possible).
(b) In case at any time after the Effective Time any further
action is necessary or desirable to carry out the purposes of this Agreement,
the proper officers and/or directors of Purchaser, the Company and the Surviving
Corporation shall use commercially reasonable efforts to take all such necessary
action.
(c) At the reasonable request of Purchaser, the Company will
use commercially reasonable efforts to cooperate with Purchaser's efforts to
obtain the Financing and the consummation of the transactions associated
therewith, provided that (i) all such information and discussions shall be
provided only to those persons executing confidentiality agreements with the
Company on terms at least as restrictive to the recipient as those contained in
the Confidentiality Agreement, (ii) the Company shall not be required to
disclose or discuss any information which the Company is not permitted to
disclose under applicable law or by contractual agreement, (iii) in no event
shall this Section 8.3(c) be deemed to require the Company to modify or agree to
modify any terms of this Agreement and (iv) in no event shall the Company's
obligations under this Section 8.3(c) be deemed to limit Purchaser's obligations
under Section 8.13 or the Company's termination rights set forth in Article X.
(d) Without limiting the foregoing, each of Purchaser and the
Company undertakes and agrees to file as soon as practicable after the date
hereof the HSR Act filing and any other filings required by antitrust
regulations of other jurisdictions including foreign countries. Each of
Purchaser and the Company shall (i) use all best efforts to comply as
expeditiously as possible with all lawful requests of the Federal Trade
Commission (the "FTC") or the Antitrust Division for additional information and
documents, and (ii) not under any circumstances whatsoever extend any waiting
period under the HSR Act or enter into any agreement with the FTC or the
Antitrust Division not to consummate the transactions contemplated by this
Agreement, except with the prior written consent of the other parties hereto,
which consent shall not be unreasonably withheld, and (iii) use all best
efforts, including litigation with the FTC or the Antitrust Division if
necessary, to cause the expeditious
39
termination of the HSR Act waiting period and the efficient and expeditious
conclusion of review by the FTC or the Antitrust Division under the HSR Act.
(e) Subject to the fiduciary duties of the Board of Directors
of the Company, the Company shall keep Purchaser informed of, and give Purchaser
the opportunity to participate in the defense or settlement of, any stockholder
or other third party litigation against the Company or its directors relating to
this Agreement and the Voting Agreements and the transactions contemplated
hereby and thereby. The Company shall not enter into any settlement of such
stockholder or other third-party litigation against the Company or its directors
which provides for injunctive relief against the Company or Purchaser or
monetary payment by the Company, in either case without the written consent of
Purchaser; provided, however, that with respect to any such settlement of
stockholder litigation against the Company or its directors providing solely for
a monetary payment, Purchaser shall not unreasonably withhold or delay such
consent.
Section 8.4 STOCKHOLDERS' APPROVAL AND BOARD OF DIRECTORS
Recommendation. (a) Subject to the terms and conditions contained herein, the
Company shall, as promptly as practicable, submit this Agreement for the
adoption by its stockholders at the Special Meeting and shall use its
commercially reasonable efforts to obtain adoption of this Agreement by its
stockholders.
(b) The Board of Directors of the Company shall recommend the
adoption of this Agreement by the stockholders of the Company in the Proxy
Statement and otherwise (the "COMPANY RECOMMENDATION"), and shall not withdraw,
modify or qualify (or propose to withdraw, modify or qualify) such
recommendation in any manner materially adverse to Purchaser or take any action
or make any statement in connection with the Special Meeting inconsistent with
such recommendation (collectively, a "CHANGE IN COMPANY RECOMMENDATION");
provided (i) the foregoing shall not prohibit disclosure (and such disclosure
shall not be deemed to be a Change in Company Recommendation) in the Proxy
Statement or otherwise of factual information regarding the business, financial
condition or results of operations of the Company or the fact that an
Alternative Proposal (as defined in Section 8.5(a)) has been made, the identity
of the Person making such proposal or the material terms of such proposal; and
(ii) that the Board of Directors of the Company may make a Change in Company
Recommendation pursuant to Section 8.5(b) hereof. Notwithstanding any Change in
Company Recommendation subsequent to the expiration of the Window Period (as
defined below), if, at the expiration of the Window Period, no Superior Proposal
(as defined in Section 8.5(b)) has been received by the Company in accordance
with the terms of this Agreement, or one or more Superior Proposals has been
received by the Company during the Window Period in respect of each of which a
Matching Offer (as defined in Section 8.5(b)) has been delivered by Purchaser to
the Company, then this Agreement shall be submitted to the stockholders of the
Company at the Special Meeting for the purpose of adopting this Agreement. As
used in this Agreement, the term "WINDOW PERIOD" shall mean the period of time
commencing on the date of this Agreement and ending at midnight New York time on
the 20th business day thereafter, unless the Company shall have furnished to
Purchaser written notice of the Company's intent to terminate this Agreement
pursuant to Section 10.4(b), which notice shall contain the material terms of a
Superior Proposal along with the name of the person or entity making the
Superior Proposal (a "NOTICE OF SUPERIOR PROPOSAL") during the final 96 hours of
such period, in which case the
40
Window Period shall expire 96 hours following Purchaser's receipt of such Notice
of Superior Proposal, and such extension of the Window Period shall be repeated
for each receipt by Purchaser of a subsequent Notice of Superior Proposal,
provided that the Window Period shall not be extended beyond such 20 business
day period in respect of a Third Party (as defined in Section 8.5(a)) who (x)
has delivered a Superior Proposal to the Company after midnight New York time on
the 20th business day following the date of this Agreement notwithstanding that
another Third Party has caused the Window Period to be extended as provided
herein or (y) has submitted a Superior Proposal prior to the 20th business day
following the date hereof but who has failed to increase its last Superior
Proposal on a timely basis in response to a Matching Offer notwithstanding that
another Third Party has caused the Window Period to be further extended as
provided herein.
Section 8.5 NO SOLICITATION. (a) The Company agrees that, except as
provided in Section 8.5(c), (i) neither it nor any of its Subsidiaries shall,
nor shall its or any of its Subsidiaries' officers, directors, employees, agents
and representatives (including, without limitation, any investment banker,
attorney or accountant retained by it or any of its Subsidiaries) initiate,
solicit or encourage, directly or indirectly, any inquiries or the making or
implementation of any proposal or offer (including, without limitation, any
proposal or offer to its stockholders) with respect to a merger, acquisition,
consolidation or similar transaction involving, or any purchase of all or any
significant portion of the assets or all or any significant portion of the
equity securities of, the Company or any of its Subsidiaries (any such proposal
or offer being referred to herein as an "ALTERNATIVE PROPOSAL"), or engage in
any negotiations concerning, or provide any information or data to, or have any
discussions with, any person other than Purchaser, Sub or any affiliates thereof
(a "THIRD PARTY") relating to an Alternative Proposal, or release any Third
Party from any obligations under any existing standstill agreement or
arrangement, or otherwise facilitate any effort or attempt to make or implement
an Alternative Proposal; and (ii) it will immediately cease and cause to be
terminated any existing activities, discussions or negotiations with any Third
Parties conducted heretofore with respect to any of the foregoing.
(b) Notwithstanding anything in this Agreement to the
contrary, the Company and its Board of Directors shall be permitted to (i) to
the extent applicable, comply with Rule 14d-9 and Rule 14e-2 promulgated under
the Exchange Act with respect to an Alternative Proposal, (ii) file a Form 8-K
with the SEC and issue a press release in accordance with Section 8.12 with
respect to the entering into of this Agreement and the transactions contemplated
hereby, including any exhibits deemed appropriate with respect to such Form 8-K
and (iii) effect a Change in Company Recommendation, if, in the case of this
clause (iii), (A) the Company receives a bona fide, written proposal or offer
relating to an Alternative Proposal by a Third Party, which the Board of
Directors determines in good faith (after consulting the Board of Directors'
independent legal and financial advisors) (I) is reasonably likely to result in
terms which are more favorable from a financial point of view to the holders of
Shares than the Merger and the other transactions contemplated by this Agreement
and (II) is reasonably capable of being consummated (provided that the Company,
including the Board of Directors, and any of its advisors shall be permitted to
contact such Third Party and its advisors solely for the purpose of clarifying
the proposal, any material contingencies and the capability of consummation)
(any such proposal or offer being referred to herein as a "SUPERIOR PROPOSAL"),
(B) the Company has furnished to Purchaser a Notice of Superior Proposal and (C)
Purchaser does not, within 48 hours
41
of Purchaser's receipt of the Notice of Superior Proposal, deliver to the
Company a binding, written offer to acquire 100% of the equity securities of the
Company (by merger or otherwise) that the Board of Directors of the Company
determines in its good faith judgment to be at least as favorable to the
Company's stockholders as such Superior Proposal (any such proposal or offer
being referred to herein as a "MATCHING OFFER"). The Company agrees that it will
use commercially reasonable efforts to inform promptly its directors, officers,
key employees, agents and representatives of the obligations undertaken in this
Section 8.5. Notwithstanding anything to the contrary in this Agreement, the
Board of Directors of the Company may effect a Change in Company Recommendation
if in the good faith opinion of the Board of Directors of the Company, after
consultation with counsel, the Company Recommendation is reasonably determined
to be inconsistent with its fiduciary duties to the Company's stockholders under
applicable law. Any such Change in Company Recommendation shall not constitute a
breach of this Agreement.
(c) Notwithstanding anything in this Agreement to the
contrary, the Company may engage in discussions or negotiations with, or provide
information to, any Person in response to a bona fide written Alternative
Proposal by any Person not solicited by the Company in violation of this Section
8.5, if and only to the extent that, (i) such Alternative Proposal constitutes a
Superior Proposal (provided that the Company, including its Board of Directors
and any of its advisors, shall be permitted to contact such Third Party and its
advisors solely for the purpose of clarifying the proposal, any material
contingencies and the capability of consummation), (ii) prior to providing any
non-public information or data to any Person in connection with an Alternative
Proposal by any such Person, the Company's Board of Directors receives from such
Person an executed confidentiality agreement containing confidentiality terms as
least as stringent as those contained in the Confidentiality Agreement referred
to in Section 8.7 (except that the confidentiality agreement to be entered into
with a Third Party does not have to contain a limit on the time period during
which information can be exchanged between the Company and the Third Party) and
(iii) concurrently with the provision of any non-public information or data to
any Person in connection with an Alternative Proposal or entering into
discussions or negotiations with any Person in connection with an Alternative
Proposal, the Company notifies Purchaser of such Alternative Proposal, any such
non-public information requested from the Company, or any such discussions or
negotiations sought to be initiated or continued with, any of the Company's
representatives indicating, in connection with such notice, the name of such
Person and the material terms and conditions of any inquiries, proposals or
offers.
(d) Nothing in this Section 8.5 shall permit the Company to
terminate this Agreement other than pursuant to Article X hereof.
Section 8.6 DIRECTORS. At the Effective Time, the Company will
obtain a resignation of each director not specified in Schedule 2.3.
Section 8.7 ACCESS TO INFORMATION, EMPLOYEES AND COMPANY PROPERTIES.
Upon reasonable notice, the Company shall (and shall cause its Subsidiaries to)
afford to the officers, employees, accountants, counsel, financial advisors and
other representatives of the Purchaser ("REPRESENTATIVES"), in order to evaluate
the transactions contemplated by this Agreement, reasonable access during normal
business hours and upon reasonable notice, during the period
42
prior to the Effective Time, to all its Company Properties, Books and Records,
contracts, commitments, records, officers and employees (other than that which
the Company is not permitted to disclose under applicable law or by contractual
agreement) and, during such period, the Company shall (and shall cause its
Subsidiaries to) furnish or make available reasonably promptly to the Purchaser
(i) a copy of each report, schedule, registration statement and other document
filed, published, announced or received by it during such period pursuant to the
requirements of federal or state securities laws, as applicable (other than
documents which such party is not permitted to disclose under applicable law or
by contractual agreement) and (ii) all other information (other than that which
the Company is not permitted to disclose under applicable law or by contractual
agreement) concerning it and its business, properties and personnel as the
Purchaser may reasonably request (including consultation on a regular basis with
respect to litigation matters). The Company shall use its commercially
reasonable efforts to cause its independent auditors to grant Purchaser and its
representatives reasonable access to the work papers prepared by such auditors
in respect of the Company for its fiscal years ended February 28, 1999, February
29, 2000 and February 28, 2001 and for periods subsequent thereto. Purchaser
agrees that it will not, and will cause its Representatives not to, use any
information obtained pursuant to this Agreement or the Confidentiality Agreement
(defined below) for any purpose unrelated to the consummation of the
transactions contemplated by this Agreement (including but not limited to the
purchase of Shares other than as contemplated by this Agreement). The
Confidential Disclosure Agreement, dated February 12, 2001, as amended by
Amendment No. 1 thereto, dated March 29, 2001 and Amendment No. 2 thereto, dated
May 29, 2001 (the "CONFIDENTIALITY AGREEMENT"), by and between the Company and
Purchaser shall apply with respect to information furnished by the Company, its
Subsidiaries and the Company's officers, employees, counsel, accountants and
other authorized representatives hereunder.
Section 8.8 SPIN-OFF. (a) The Company shall use commercially
reasonable efforts to satisfy the conditions to the Spin-off set forth in
Section 3.3 of the Separation Agreement and shall effect the Spin-Off if such
conditions have been satisfied. The Company shall cause Life Sciences to comply
with its obligations under the Separation Agreement. Notwithstanding anything in
this Section 8.8 to the contrary, the parties acknowledge and agree that this
Section 8.8 shall not require the Company or Life Sciences to waive any
condition to the Spin-Off set forth in the Separation Agreement.
(b) The Company shall keep Purchaser informed on a regular
basis concerning material developments in the transactions contemplated by the
Spin-Off Agreements and the means by which such transactions are effected.
Section 8.9 GOVERNMENTAL FILINGS. The Company and Purchaser shall
promptly provide each other (or their respective counsel) copies of all filings
made by such party with the SEC or any other Governmental Entity or Industry
Compliance Entity in connection with this Agreement and the transactions
contemplated hereby.
Section 8.10 TIMELY PAYMENT. Purchaser shall use commercially
reasonable efforts, and shall cause its Subsidiaries to use commercially
reasonable efforts, to pay promptly all invoiced amounts due to the Company and
its Subsidiaries for Company Products and Services sold by the Company or its
Subsidiaries to Purchaser or Purchaser's Subsidiaries.
43
Section 8.11 STANDSTILL AGREEMENT. (a) Except as provided in Section
8.11(b) and contemplated by this Agreement and the transactions contemplated
hereby or in connection with the execution and consummation of the Voting
Agreements, Purchaser agrees that, unless authorized by the Board of Directors
of the Company in writing, neither Purchaser nor any of its affiliates (as such
term is defined in the Exchange Act) will in any manner, directly or indirectly,
(i) effect or seek, offer or propose (whether publicly or otherwise) to effect,
or cause or participate in or in any way assist any other Person to effect or
seek, offer or propose (whether publicly or otherwise) to effect, or cause or
participate in, (A) any acquisition of Common Stock or other voting securities
of the Company; (B) any tender or exchange offer, merger or other business
combination involving the Company; (C) any recapitalization, restructuring,
liquidation, dissolution or other extraordinary transaction with respect to the
Company; or (D) any "solicitation" of "proxies" (as such terms are used in the
proxy rules of the SEC) or other agreements to vote any shares of Common Stock
or other voting securities of the Company; (ii) form, join or in any way
participate in a "group" (as defined in the Exchange Act) or otherwise act,
alone or in concert with others, to seek to control or influence the management,
Board of Directors or policies of the Company; (iii) take any action which might
force the Company to make a public announcement regarding any of the types of
matters set forth in subsection (i) above; or (iv) enter into any discussions or
arrangements with any Third Party with respect to any of the foregoing.
(b) Notwithstanding anything in this Agreement to the
contrary, in the event that a Third Party shall commence a tender or exchange
offer for more than 25% of the outstanding voting securities of the Company,
nothing herein shall prevent Purchaser from, after termination of the Voting
Agreements, commencing a tender offer to purchase any outstanding voting
securities of the Company in response thereto.
Section 8.12 PUBLIC ANNOUNCEMENTS. The Company and Purchaser will
consult with each other before issuing any press release or making any public
statement with respect to this Agreement and the transactions contemplated
hereby and, except as may be required by applicable law or any listing agreement
with any national securities exchange or any organization providing stock
quotations, will not issue any such press release or make any such public
statement prior to such consultation. The initial press release announcing the
execution of this Agreement shall be made jointly by the Company and Purchaser
promptly after the execution hereof.
Section 8.13 FINANCING. Purchaser shall (i) use commercially
reasonable efforts to ensure that the conditions described in the Commitment
Letter are fulfilled on or before September 30, 2001 and (ii) promptly inform
the Company in writing (a "FINANCING NOTICE") if at any time (A) the Commitment
Letter ceases to be in full force and effect, (B) Purchaser becomes aware of any
fact, occurrence or condition that would cause the Commitment Letter to be
terminated or ineffective or any of the conditions therein not to be met, unless
Purchaser reasonably believes that any such fact, occurrence or condition may be
cured by Purchaser or waived by the lender thereunder within thirty (30)
calendar days of the date on which Purchaser became aware of such fact,
occurrence or condition, or (C) Purchaser believes that the funding pursuant to
the Commitment Letter in the full amount of the Financing is not likely to
occur. Notwithstanding anything to the contrary contained in this Agreement, in
the event that Purchaser is able to obtain Financing from a financing source
other than pursuant to the
44
Commitment Letter on terms at least as favorable and no more burdensome to the
Company than the terms contained in the Commitment Letter, Purchaser may
terminate the Commitment Letter in favor of a new commitment letter and
Financing from such new or alternative financing source (a "New Commitment
Letter"), provided that Purchaser shall not have the right to terminate the
Commitment Letter in favor of a New Commitment Letter if such termination would
delay the consummation of the Merger past October 15, 2001. In the event that
Purchaser shall terminate the Commitment Letter in favor of a New Commitment
Letter, references in this Agreement to the Commitment Letter shall be replaced
with references to the New Commitment Letter such that Purchaser's obligations
with respect to delivering a Financing Notice shall apply to such New Commitment
Letter, and in no event shall the replacement of the Commitment Letter for a New
Commitment Letter limit the Company's termination rights in Article X hereof.
For the avoidance of doubt, any termination of the Commitment Letter in favor of
a New Commitment Letter in accordance with Section 8.13 shall not constitute a
breach of this Agreement.
ARTICLE IX
CONDITIONS PRECEDENT
Section 9.1 CONDITIONS TO EACH PARTY'S OBLIGATION TO EFFECT THE
Merger. The respective obligation of each party to effect the Merger shall be
subject to the fulfillment at or prior to the Effective Time of the following
conditions:
(a) STOCKHOLDER APPROVAL. This Agreement shall have been
adopted by the requisite vote of the holders of the Shares.
(b) ANTITRUST APPROVALS. The waiting period applicable to the
consummation of the Merger under the HSR Act shall have expired or been
terminated.
(c) NO INJUNCTION. No preliminary or permanent injunction or
other order by any federal or state court in the United States of competent
jurisdiction which prevents the consummation of the Merger shall have been
issued and remain in effect (each party agreeing to use all commercially
reasonable efforts to have any such injunction lifted).
(d) NO LEGISLATION. No action shall have been taken, and no
statute, rule or regulation shall have been enacted, by any state or federal
government, Governmental Entity or Industry Compliance Entity in the United
States which would prevent the consummation of the Merger or make the
consummation of the Merger illegal.
(e) COMPLETION OF DISTRIBUTION. The Distribution (as defined
in the Separation Agreement) shall have been consummated in accordance with the
terms and subject to the conditions set forth in the Separation Agreement.
(f) FINANCING. The Company shall not have received a Financing
Notice and Purchaser shall not have become obligated to deliver a Financing
Notice to the Company. The receipt by the Company of a Financing Notice or the
occurrence of the
45
obligation of Purchaser to deliver a Financing Notice, shall be deemed a failure
of the condition contained in this Section 9.1(f) that cannot be satisfied or
cured.
Section 9.2 ADDITIONAL CONDITIONS TO OBLIGATION OF THE COMPANY TO
EFFECT THE MERGER. The obligation of the Company to effect the Merger shall be
subject to the fulfillment at or prior to the Effective Time of the following
additional conditions, unless waived by the Company:
(a) COMPLIANCE WITH AGREEMENT; OFFICER'S CERTIFICATE.
(i) (A) Purchaser and Sub shall have performed in all
material respects all of their agreements
contained in this Agreement required to be
performed on or prior to the Closing Date.
(B) All the representations and warranties of
Purchaser and Sub contained in this Agreement,
which are qualified by reference to a Material
Adverse Effect, must be true and correct as of the
date of this Agreement and must be true and
correct in all material respects as of the Closing
Date as if made on the Closing Date (except to the
extent they relate to a particular date other than
the Closing Date).
(C) All the representations and warranties of
Purchaser and Sub contained in this Agreement,
which are not qualified by reference to a Material
Adverse Effect, must be true and correct as of the
date of this Agreement and must be true and
correct on the Closing Date as if made on the
Closing Date (except to the extent they relate to
a particular date other than the Closing Date),
except where the failure of such representations
and warranties to be true and correct as of the
date of this Agreement and as of the Closing Date
would not, either individually or in the
aggregate, have a Material Adverse Effect on
Purchaser or Sub. For purposes of this Section
9.2(a)(i)(C) all references to Material Adverse
Effect, "material" or "materially" contained in
any of Purchaser's or Sub's representations and
warranties shall be disregarded.
(D) The Company shall have received a certificate of
the Chief Executive Officer of each of Purchaser
and Sub that (I) Purchaser and Sub have performed
in all material respects all of their agreements
required to be performed on or prior to the
Closing Date and (II) the representations and
warranties contained in this Agreement are true
and correct as of the date of this Agreement and
as of the Closing Date as if made on the Closing
Date (except to the extent they relate to a
particular date other than the Closing Date), and
46
except as specifically identified and described in
reasonable detail in such certificate.
(b) INCUMBENCY CERTIFICATES. The Company shall have received a
certificate of the Secretary or an Assistant Secretary of each of Purchaser and
Sub certifying the names and signatures of the officers of each of Purchaser and
Sub authorized to sign this Agreement and all related documents to be delivered
by Purchaser and Sub hereunder.
(c) GOOD STANDING CERTIFICATE. The Company shall have received
a recently dated good standing certificate for Sub from the Secretary of State
of the State of Delaware.
(d) BOARD RESOLUTIONS. The Company shall have received true
and complete copies of resolutions duly and validly adopted by the Board of
Directors of each of Purchaser and Sub, evidencing the respective authorization
of the execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby, accompanied by a certificate of the Secretary
or Assistant Secretary of each of Purchaser and Sub, dated as of the Closing
Date, stating that no amendments have been made thereto from the date thereof
through the Closing Date.
Section 9.3 ADDITIONAL CONDITIONS TO OBLIGATION OF PURCHASER AND SUB
TO EFFECT THE MERGER. The obligations of Purchaser and Sub to effect the Merger
shall be subject to the fulfillment at or prior to the Effective Time of the
following additional conditions, unless waived by Purchaser:
(a) COMPLIANCE WITH AGREEMENT; OFFICER'S CERTIFICATE.
(i) (A) The Company shall have performed in all
material respects all of its agreements contained
in this Agreement required to be performed on or
prior to the Closing Date.
(B) Subject to Section 9.3(a)(ii), all the
representations and warranties of the Company
contained in this Agreement, which are qualified
by reference to a Material Adverse Effect, must be
true and correct as of the date of this Agreement
and must be true and correct in all material
respects as of the Closing Date as if made on the
Closing Date (except to the extent they relate to
a particular date other than the Closing Date).
(C) Subject to Section 9.3(a)(ii), all the
representations and warranties of the Company
contained in this Agreement, which are not
qualified by reference to a Material Adverse
Effect, must be true and correct as of the date of
this Agreement and must be true and correct on the
Closing Date as if made on the Closing Date
(except to the extent they relate to a particular
date other than the Closing Date), except where
the failure of such representations and
47
warranties to be true and correct as of the date
of this Agreement and as of the Closing Date would
not, either individually or in the aggregate, have
a Material Adverse Effect on the Company or the
Company after giving effect to the Spin-Off. For
purposes of this Section 9.3(a)(i)(C) all
references to Material Adverse Effect, "material"
or "materially" contained in any of the Company's
representations and warranties shall be
disregarded.
(D) Purchaser and Sub shall have received a
certificate of the Chief Executive Officer of the
Company that (I) the Company has performed in all
material respects all of its agreements required
to be performed on or prior to the Closing Date
and (II) the representations and warranties
contained in this Agreement are true and correct
as of the date of this Agreement and as of the
Closing Date as if made on the Closing Date
(except to the extent they relate to a particular
date other than the Closing Date), and except as
specifically identified and described in
reasonable detail in such certificate.
(ii) the requirement of the Company's representations and
warranties as applied to the Life Sciences Business (as defined in the
Spin-Off Agreements) to be true in all respects or in all material
respects, as the case may be, as of the date hereof or the Closing Date,
shall not be deemed to be a condition to the obligation of Purchaser and
Sub to effect the Merger.
(b) NO ADVERSE DEVELOPMENTS. Since the date hereof, there
shall have been no changes that constitute, and no event or events shall have
occurred which have resulted in or constitute, a Material Adverse Change in
respect of the Company (after giving effect to the Spin-Off).
(c) CONSENTS AND APPROVALS. All waivers, consents, orders,
authorizations, and approvals set forth on Schedule 9.3(c) shall have been
obtained, provided that the Company's failure to obtain five or fewer of the
consents in respect of the leases set forth on Schedule 9.3(c) shall not be
deemed to be a condition to the obligation of Purchaser and Sub to effect the
Merger.
(d) SECRETARY'S CERTIFICATE. Purchaser shall have received a
certificate, dated the Closing Date, of the Secretary of the Company attaching
(i) a true and complete copy of the Certificate of Incorporation of the Company,
with all amendments thereto, certified by the Secretary of State of the State of
Delaware, (ii) true and complete copies of the Company's By-Laws in effect as of
such date, (iii) certificates of good standing of the appropriate officials of
the jurisdictions of incorporation of the Company and each Subsidiary as of a
recent date, and (iv) resolutions of the Board of Directors of the Company
authorizing the execution and delivery of the Agreement and the transactions
contemplated thereby (and such Secretary's Certificate
48
shall state that no amendments to such resolutions shall have been made thereto
from the date of such resolutions through the Closing Date).
(e) INCUMBENCY CERTIFICATE. Purchaser shall have received an
incumbency certificate of the Company, certifying as to the names and signatures
of the persons authorized on behalf of the Company to execute this Agreement and
all related documents to be delivered by the Company hereunder.
(f) CANCELLATION OF OPTIONS AND WARRANTS. Except as set forth
on Section 3.5 of the Company Disclosure Letter, Options and Warrants
representing at least 95% of the Shares issuable upon the exercise of all
Options and Warrants outstanding as of the date hereof shall have been
exercised, canceled in accordance with their terms, or the holders thereof shall
have consented (unless such treatment is provided for in the applicable Option
or Warrant) to their cancellation or an amendment thereto in respect of such
holders' right to receive the excess of the Merger Consideration over the per
share Adjusted Exercise Price of such Option or Warrant pursuant to this
Agreement, and documentation evidencing same shall have been delivered to
Purchaser.
(g) DIRECTOR RESIGNATIONS. The directors of the Company not
named on Schedule 2.3 shall have delivered written resignations (which
resignations shall be effective as of the Effective Time unless an earlier date
is specified in the respective resignation) to Purchaser.
(h) FIRPTA CERTIFICATE. The Company shall have delivered to
Purchaser a certificate, as contemplated under and meeting the requirements of
Treasury Regulations Section 1.897-2(g)(1)(ii) and 1.897-2(h)(1)(i), to the
effect that as of the date hereof, giving effect to the Spin-Off, no interest in
the Company constitutes a "United States real property interest" within the
meaning of Section 897(c) of the Code.
(i) CERTAIN FINANCIAL THRESHOLDS. Each of the following
financial and performance thresholds of the Company shall be true and correct in
all respects: (i) the total assets of the Company and its Subsidiaries,
excluding the total assets of Life Sciences, as of February 28, 2001 (determined
on the basis of the assumptions set forth in the Pro Forma Balance Sheet for the
fiscal year ended February 28, 2001), are not less than 90% of the total assets
of the Company and its Subsidiaries, excluding the total assets of Life
Sciences, reflected in the Pro Forma Balance Sheet for the fiscal year ended
February 28, 2001 (the "Pro Forma Total Assets"); (ii) the total liabilities of
the Company and its Subsidiaries, excluding the total liabilities of Life
Sciences, as of February 28, 2001 (determined on the basis of the assumptions
set forth in the Pro Forma Balance Sheet for the fiscal year ended February 28,
2001), are not more than 110% of the total liabilities of the Company and its
Subsidiaries, excluding the total liabilities of Life Sciences, reflected in the
Pro Forma Balance Sheet for the fiscal year ended February 28, 2001 (the "Pro
Forma Total Liabilities"); (iii) the total revenues of the Company and its
Subsidiaries, excluding the total revenues of Life Sciences, for the fiscal year
ended February 28, 2001 (determined on the basis of the assumptions set forth in
the Pro Forma Income Statement for the fiscal year ended February 28, 2001), are
not less than 95% of the total revenues of the Company and its Subsidiaries,
excluding the total revenues of Life Sciences, as reflected in the Pro Forma
Income Statement for the fiscal year ended February 28, 2001 (the
49
"Pro Forma Total Revenues"); and (iv) the Company's Annual Plasma Volume for the
fiscal year ended February 28, 2001 is not less than 95% of the Annual Plasma
Volume as provided in Section 5.28 for the Company's fiscal year ended February
28, 2001. The thresholds specified in the foregoing sentence shall not be deemed
to imply any materiality threshold for any other purpose of this Agreement. In
the event that the thresholds specified in this Section 9.3(i) are true and
correct, but there are discrepancies between any of the Pro Forma Total Assets,
Pro Forma Total Liabilities, Pro Forma Total Revenues or Annual Plasma Volume
and the actual amounts, such differences shall not be deemed a breach by the
Company or any of its Subsidiaries of any of the representation and warranties
in this Agreement and such differences shall not be taken into account in
determining whether or not there has been a Material Adverse Effect on the
Company or other failure of the condition set forth in Section 9.3(a).
(j) CONFIRMATION OF TERMS OF SUPPLY AGREEMENTS. Purchaser
shall have (i) had an opportunity to review all current agreements between the
Company and its Customers or (ii) received a certificate from Xxxxx Xxxxx or
Xxxxx Xxxxxxx substantially in the form of Exhibit A hereto.
ARTICLE X
TERMINATION, AMENDMENT AND WAIVER
Section 10.1 TERMINATION BY MUTUAL CONSENT. This Agreement may be
terminated and the Merger may be abandoned at any time prior to the Effective
Time, before or after the adoption of this Agreement by the stockholders of the
Company, by the mutual written consent of Purchaser, Sub and the Company.
Section 10.2 TERMINATION BY EITHER PURCHASER OR THE COMPANY. This
Agreement may be terminated and the Merger may be abandoned by action of the
Board of Directors of the Company or the Purchaser if (a) the Merger shall not
have been consummated by the earlier to occur of (i) December 31, 2001 and (ii)
the later of (A) October 31, 2001, (B) 45 calendar days after the Proxy
Statement shall have been approved by the SEC or (C) 30 calendar days after the
Form 10 Registration Statement (as defined in the Spin-Off Agreements) shall
have been declared effective by the SEC, (b) the Special Meeting shall have been
held and the stockholders of the Company shall have failed to adopt this
Agreement thereat or at any adjournment or postponement thereof, or (c) a United
States federal or state court of competent jurisdiction or United States federal
or state governmental, regulatory or administrative agency or commission shall
have issued an order, decree or ruling or taken any other action permanently
restraining, enjoining or otherwise prohibiting the transactions contemplated by
this Agreement and such order, decree, ruling or other action shall have become
final and non-appealable; provided that the party seeking to terminate this
Agreement pursuant to clause (c) above shall have used all commercially
reasonable efforts to remove such injunction, order or decree; and provided, in
the case of a termination pursuant to clause (a) or (b) above, that the
terminating party shall not have breached in any material respect its
obligations under this Agreement in any manner that shall have proximately
contributed to the failure to consummate the Merger.
50
Section 10.3 TERMINATION BY PURCHASER. This Agreement may be
terminated and the Merger may be abandoned at any time prior to the Effective
Time by the Purchaser, if (a) the Board of Directors of the Company shall have
effected a Change in Company Recommendation or (b) any of the conditions
specified in Sections 9.1 and 9.3 shall have not been met or waived by Purchaser
at such time as such condition can no longer be satisfied; provided that the
right of Purchaser to terminate this Agreement pursuant to clause (b) of this
Section 10.3 shall not be available to Purchaser if Purchaser's failure to
fulfill any obligation under this Agreement has been the cause of or resulted in
the failure of any such condition.
Section 10.4 TERMINATION BY THE COMPANY. This Agreement may be
terminated and the Merger abandoned by the Company if (a) any of the conditions
specified in Sections 9.1 and 9.2 shall not have been met or waived by the
Company at such time as such condition can no longer be satisfied or (b) (i)
prior to the expiration of the Window Period, the Company shall have received a
Superior Proposal not solicited by the Company in violation of Section 8.5, (ii)
the Company has furnished to Purchaser a Notice of Superior Proposal and (iii)
Purchaser does not, within 48 hours of Purchaser's receipt of the last of one or
more Notice(s) of Superior Proposal, deliver to the Company a Matching Offer
with respect to the last such Notice of Superior Proposal; provided that the
right of the Company to terminate this Agreement pursuant to clause (a) of this
Section 10.4 shall not be available to the Company if the Company's failure to
fulfill any obligation under this Agreement has been the cause of or resulted in
the failure of any such condition.
Section 10.5 EFFECT OF TERMINATION AND ABANDONMENT. (a) As used
herein a "PURCHASER TERMINATION FEE EVENT" shall mean (i) the Board of Directors
of the Company shall have effected a Change of Company Recommendation and the
approval of the Company's stockholders shall not have been obtained at the
Special Meeting or at any adjournment or postponement thereof and Purchaser
shall have terminated this Agreement pursuant to Section 10.3(a); (ii) Purchaser
shall have terminated this Agreement pursuant to Section 10.3(a); (iii)
Purchaser shall have terminated this Agreement pursuant to Section 10.3(b)
solely because any of the conditions contained in Section 9.3(a), 9.3(d) (except
for 9.3(d)(iii)) or 9.3(e) through 9.3(j) shall not have been met or waived by
Purchaser at such time as any such condition can no longer be satisfied,
provided that the termination by Purchaser of this Agreement pursuant to Section
10.3(b) solely for a failure of the condition contained in Section 9.3(f) shall
not be a Purchaser Termination Fee Event as long as the Company shall have used
commercially reasonable efforts to obtain the consents contemplated by Section
9.3(f) and at least 90% of the Shares issuable upon the exercise of Options and
Warrants outstanding as of the date hereof shall have been exercised, cancelled
in accordance with their terms, or the holders thereof shall have consented
(unless such treatment is provided for in the applicable Options or Warrants) to
their cancellation or an amendment to the agreement in respect thereof as
contemplated by Section 9.3(f), provided that no termination pursuant to this
clause (iii) shall be deemed a Purchaser Termination Fee Event if, at the time
of such termination, the condition specified in Section 9.1(f) has not been met,
unless the failure of the condition specified in Section 9.1(f) to have been met
is the direct result of the failure of a condition in Section 9.1(a) through
9.1(e) or 9.3; (iv) the Company shall have terminated this Agreement pursuant to
Section 10.4(b); or (v) (A) any Person shall have made a Superior Proposal and
(B) thereafter this Agreement is terminated for any reason other than pursuant
to Section 10.4(a) or those set forth in clause (i), (ii), (iii) or (iv) of this
Section 10.5 and (C) within 15 months thereafter such Superior Proposal shall
have
51
been consummated. In the event that a Purchaser Termination Fee Event shall
have occurred, then the Company shall promptly, but in no event later than two
business days after such Termination Fee Event, pay Purchaser a fee of
$3,450,000 (the "PURCHASER TERMINATION FEE") plus the Purchaser Expenses (as
defined below).
(b) As used herein a "COMPANY TERMINATION FEE EVENT" shall
mean (i) the Company shall have terminated this Agreement pursuant to Section
10.4(a) solely because the condition contained in Section 9.1(f) shall not have
been met at such time as such condition can no longer be satisfied, unless the
failure of the condition contained in Section 9.1(f) to have been met is the
direct result of the failure of a condition in Section 9.1(a) through 9.1(e) or
9.3; (ii) the Company shall have terminated this Agreement pursuant to Section
10.4(a) solely because any of the conditions contained in Section 9.2(b) or
9.2(d) shall not have been met or waived by the Company at such time as any such
condition can no longer be satisfied; (iii) this Agreement is terminated by
Purchaser pursuant to Section 10.3(b) solely because of the failure of a
condition contained in Section 9.1, at a time when the condition contained in
Section 9.1(f) shall not have been met at such time as such condition can no
longer be satisfied, unless the failure of the condition contained in Section
9.1(f) to have been met is the direct result of the failure of a condition in
Section 9.1(a) through 9.1(e) or 9.3; or (iv) this Agreement is terminated by
Purchaser or the Company pursuant to Section 10.2(a) at a time when the
condition contained in Section 9.1(f) shall not have been met at such time as
such condition can no longer be satisfied, unless the failure of the condition
contained in Section 9.1(f) to have been met is the direct result of the failure
of a condition in Section 9.1(a) through 9.1(e) or 9.3. In the event that a
Company Termination Fee Event shall have occurred, then Purchaser shall
promptly, but in no event later than two business days after such termination,
pay the Company a fee of $3,450,000 (the "COMPANY TERMINATION FEE") plus the
Company Expenses (as defined below).
(c) In the event this Agreement is terminated by Purchaser
pursuant to Section 10.2(b) or Section 10.3(b) (but solely because of a failure
of a condition specified in Section 9.3(b) and not because of the failure of a
condition specified in Section 9.1, 9.3(a) or 9.3(c) through 9.3(j)), then the
Company shall promptly reimburse Purchaser for up to $1,500,000 of documented
out-of-pocket costs and expenses incurred by Purchaser in connection with this
Agreement and the transactions contemplated hereby, including, but not limited
to costs and expenses of accountants, attorneys and financial advisors (the
"PURCHASER EXPENSES"). Notwithstanding anything herein to the contrary, the
Company shall have no obligation to reimburse Purchaser for the Purchaser
Expenses if Purchaser or the Company terminates this Agreement at a time when
the condition contained in Section 9.1(f) shall not have been met at such time
as such condition can no longer be satisfied, unless the failure of the
condition contained in Section 9.1(f) to have been met is the direct result of
the failure of a condition in Section 9.1(a) through 9.1(e) or 9.3.
(d) In the event this Agreement is terminated by the Company
pursuant to Section 10.4(a) but solely because of a failure of a condition
specified in 9.2(a) and not because of a failure of a condition specified in
Section 9.1 or Section 9.2(b) through (d), then Purchaser shall promptly
reimburse the Company for up to $1,500,000 of documented out-of-pocket costs and
expenses incurred by the Company in connection with this Agreement and the
transactions contemplated hereby, including, but not limited to costs and
expenses of accountants, attorneys and financial advisors (the "COMPANY
EXPENSES").
52
(e) The Company acknowledges that the agreements contained in
this Section 10.5 are an integral part of the transactions contemplated by this
Agreement, and that without these agreements, Purchaser and Sub would not enter
into this Agreement; accordingly, if the Company fails to pay promptly amounts
due pursuant to this Section 10.5, and, in order to obtain such payment,
Purchaser or Sub commences a suit which results in a judgment against the
Company for the Purchaser Termination Fee and Purchaser Expenses, the Company
shall pay to Purchaser its costs and expenses (including reasonable attorneys'
fees) in connection with such suit, together with interest on the amount of the
Purchaser Termination Fee and Purchaser Expenses at the rate of 12% per annum
compounded quarterly (but in no event at a rate in excess of the rate permitted
by Delaware law).
(f) Purchaser and Sub acknowledge that the agreements
contained in this Section 10.5 are an integral part of the transactions
contemplated by this Agreement, and that without these agreements, the Company
would not enter into this Agreement; accordingly, if Purchaser fails to pay
promptly amounts due pursuant to this Section 10.5, and, in order to obtain such
payment, the Company commences a suit which results in a judgment against
Purchaser for the Company Termination Fee and the Company Expenses, Purchaser
shall pay to the Company its costs and expenses (including reasonable attorneys'
fees) in connection with such suit, together with interest on the amount of such
Company Termination Fee and Company Expenses at the rate of 12% per annum
compounded quarterly (but in no event at a rate in excess of the rate permitted
by Delaware law).
(g) In the event of termination of this Agreement and the
abandonment of the Merger pursuant to this Article X, all obligations of the
parties hereto shall terminate, except the obligations of the parties pursuant
to this Section 10.5, Section 11.1, Section 11.3 and the last two sentences of
Section 8.7.
ARTICLE XI
MISCELLANEOUS
Section 11.1 NON-SURVIVAL OF REPRESENTATIONS, WARRANTIES AND
Agreements. All representations and warranties set forth in this Agreement or in
any instrument delivered pursuant to this Agreement shall terminate at the
earlier to occur of (i) the termination of this Agreement and (ii) the Effective
Time.
Section 11.2 NOTICES. All notices or other communications under this
Agreement shall be in writing and shall be given (and shall be deemed to have
been duly given upon receipt) by delivery in person, by cable, telegram, telex
or other standard form of telecommunications, or by registered or certified
mail, postage prepaid, return receipt requested, addressed as follows:
If to the Company:
SeraCare, Inc.
0000 Xxxxxxx Xxxx Xxxx, Xxxxx 0000
Xxx Xxxxxxx, Xxxxxxxxxx 00000
53
Attention: Xx. Xxxxx Xxxxx
Telecopy No.: (000) 000-0000
With a copy to:
O'Melveny & Xxxxx LLP
000 Xxxxxxx Xxxxxx Xxxxx, Xxxxx 0000
Xxxxxxx Xxxxx, Xxxxxxxxxx 00000
Attention: Xxxxx X. Xxxxxxx, Esq.
Telecopy No.: (000) 000-0000
If to Purchaser or Sub:
Instituto Grifols, S.A.
c/o Grupo Grifols, S.A.
X/ xx xx Xxxxxx, 00-00
Xxxxx Xxxxxx, Xx. 00
00000 Xxxxxxxxx
Xxxxx
Attention: Xx. Xxxxxx Grifols
Telecopy No.: 34 93 571 0267
54
With a copy to:
Proskauer Rose LLP
0000 Xxxxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attention: Xxxxxx X. Xxxxxx, Esq.
Telecopy No.: (000) 000-0000
or to such other address as any party may have furnished to the other parties in
writing in accordance with this Section.
Section 11.3 FEES AND EXPENSES. Whether or not the Merger is
consummated, except as provided in Section 10.5, all costs and expenses incurred
in connection with this Agreement and the transactions contemplated by this
Agreement shall be paid by the party incurring such expenses.
Section 11.4 PUBLICITY. So long as this Agreement is in effect,
Purchaser, Sub and the Company agree to consult with each other in issuing any
press release or otherwise making any public statement with respect to the
transactions contemplated by this Agreement, and none of them shall issue any
press release or make any public statement prior to such consultation, except as
may be required by law or by obligations pursuant to any listing agreement with
any national securities exchange.
Section 11.5 SPECIFIC PERFORMANCE. The parties hereto agree that
irreparable damage would occur in the event that any of the provisions of this
Agreement were not performed in accordance with their specific terms or were
otherwise breached. It is accordingly agreed that the parties shall be entitled
to an injunction or injunctions to prevent breaches of this Agreement and to
enforce specifically the terms and provisions hereof in the United States
District Court for the District of Delaware or the State Courts of Delaware,
this being in addition to any other remedy to which they are entitled at law or
in equity.
Section 11.6 ASSIGNMENT; BINDING EFFECT. Neither this Agreement nor
any of the rights, interests or obligations hereunder shall be assigned by any
of the parties hereto (whether by operation of law or otherwise) without the
prior written consent of the other parties. Notwithstanding anything contained
in this Agreement to the contrary, nothing in this Agreement, expressed or
implied, other than the right to receive the consideration payable in the Merger
pursuant to Article III hereof, is intended to confer on any person other than
the parties hereto or their respective successors and assigns any rights,
remedies, obligations or liabilities under or by reason of this Agreement;
provided that the Indemnified Parties shall be third-party beneficiaries of
Purchaser's agreement contained in Section 8.2 hereof.
Section 11.7 ENTIRE AGREEMENT. This Agreement (including the
documents and instruments referred to herein) and the Confidentiality Agreement
constitute the entire agreement among the parties with respect to the subject
matter hereof and supersede all prior agreements and understandings among the
parties with respect thereto. No addition to or modification of any provision of
this Agreement shall be binding upon any party hereto unless made in writing and
55
signed by all parties hereto. In the event of any conflict between the terms of
this Agreement and the terms of the Confidentiality Agreement, the terms of this
Agreement shall prevail.
Section 11.8 AMENDMENT. This Agreement may be amended by the parties
hereto at any time before or after approval of matters presented in connection
with the Merger by the stockholders of the Company, but after any such
stockholder approval, no amendment shall be made which by law requires the
further approval of stockholders without obtaining such further approval. This
Agreement may not be amended except by an instrument in writing signed on behalf
of each of the parties hereto.
Section 11.9 GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD
TO ITS RULES REGARDING CONFLICTS OF LAWS.
Section 11.10 CONSENT TO JURISDICTION. Each of the parties hereto
irrevocably submits to the exclusive jurisdiction of the United States District
Court for the District of Delaware and the state courts of the State of
Delaware, for the purposes of any suit, action or other proceeding arising out
of this Agreement or any transaction contemplated hereby. To the fullest extent
permitted by law, each of the parties hereto further agrees that service of any
process, summons, notice or document by U.S. certified or registered mail to
such party's respective address set forth in Section 11.2 shall be effective
service of process in any action, suit or proceeding in Delaware with respect to
any matters to which it has submitted to jurisdiction as set forth in the
immediately preceding sentence. Purchaser and the Company hereby appoint
Paracorp Incorporated as their agent for service of process in Delaware for any
suit arising hereunder. Each of the parties hereto irrevocably and
unconditionally waives any objection to the laying of venue of any action, suit
or proceeding arising out of this Agreement or the transactions contemplated
hereby in the United States District Court for the District of Delaware or the
state courts of Delaware, and hereby irrevocably and unconditionally waives and
agrees not to plead or claim in any such court that any such action, suit or
proceeding brought in such court has been brought in an inconvenient forum. Each
of the parties hereby irrevocably waives, to the fullest extent permitted by
law, all rights to trial by jury in any action, proceeding or counterclaim
(whether based upon contract, tort or otherwise) arising out of or relating to
this Agreement or any of the transactions contemplated hereby.
Section 11.11 COUNTERPARTS. This Agreement may be executed by the
parties hereto in separate counterparts, each of which when so executed and
delivered shall be an original, but all such counterparts shall together
constitute one and the same instrument.
Section 11.12 HEADINGS AND TABLE OF CONTENTS. Headings of the
Articles and Sections of this Agreement and the Table of Contents are for the
convenience of the parties only, and shall be given no substantive or
interpretive effect whatsoever.
Section 11.13 INTERPRETATION. In this Agreement, unless the context
otherwise requires, words describing the singular number shall include the
plural and vice versa, and words denoting any gender shall include all genders
and words denoting natural persons shall include corporations and partnerships
and vice versa.
56
Section 11.14 WAIVERS. The conditions to each of the parties'
obligations to consummate the Merger are for the sole benefit of such party and
may be waived by such party in whole or in part to the extent permitted by
applicable law. Any agreement on the part of a party hereto to any such
extension or waiver shall be valid if set forth in an instrument in writing
signed on behalf of such party. Except as provided in this Agreement, no action
taken pursuant to this Agreement, including, without limitation, any
investigation by or on behalf of any party, shall be deemed to constitute a
waiver by the party taking such action of compliance with any representations,
warranties, covenants or agreements contained in this Agreement. The waiver by
any party hereto of a breach of any provision hereunder shall not operate or be
construed as a waiver of any prior or subsequent breach of the same or any other
provision hereunder.
Section 11.15 INCORPORATION OF DOCUMENT. The Company Disclosure
Letter and all Schedules and Exhibits attached hereto and referred to herein are
hereby incorporated herein and made a part hereof for all purposes as if fully
set forth herein.
Section 11.16 SEVERABILITY. Any term or provision of this Agreement
which is invalid or unenforceable in any jurisdiction shall, as to that
jurisdiction, be ineffective to the extent of such invalidity or
unenforceability without rendering invalid or unenforceable the remaining terms
and provisions of this Agreement or affecting the validity or enforceability of
any of the terms or provisions of this Agreement in any other jurisdiction. If
any provision of this Agreement is so broad as to be unenforceable, the
provision shall be interpreted to be only so broad as is enforceable.
Section 11.17 SUBSIDIARIES; KNOWLEDGE OF THE COMPANY. As used in
this Agreement, the word "SUBSIDIARY" when used with respect to any party means
any corporation or other organization, whether incorporated or unincorporated,
of which such party directly or indirectly owns or controls at least a majority
of the securities or other interests having by their terms ordinary voting power
to elect a majority of the board of directors or others performing similar
functions with respect to such corporation or other organization, or any
organization of which such party is a general partner. As used in this
Agreement, the term "KNOWLEDGE" with respect to the Company and its Subsidiaries
shall mean actual knowledge of any of the executive officers and directors of
the Company or its applicable Subsidiary.
57
IN WITNESS WHEREOF, Purchaser, Sub and the Company have caused this
Agreement to be signed by their respective officers thereunder duly authorized
all as of the date first written above.
INSTITUTO GRIFOLS, S.A.
By: /s/ Xxxxxx Grifols
---------------------------------------
Print name: Xxxxxx Grifols
Title: Chief Executive Officer
SI MERGER CORP.
By: /s/ Xxxxxx Grifols
---------------------------------------
Print name: Xxxxxx Grifols
Title: President
SERACARE, INC.
By: /s/ Xxxxx Xxxxx
---------------------------------------
Print name: Xxxxx Xxxxx
Title: Chief Executive Officer
58
